var title_f10_25_10640="Hip bursae PI";
var content_f10_25_10640=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F65477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F65477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bursae near the hip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 412px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These sacs, called \"bursae\", are filled with fluid. They help cushion and protect the joints. \"Bursitis\" is the medical term for when one of these sacs get irritated or inflamed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_25_10640=[""].join("\n");
var outline_f10_25_10640=null;
var title_f10_25_10641="Female condom PI";
var content_f10_25_10641=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F59955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F59955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Female condom",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 201px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    One of the rings of the female condom rests inside the woman's vagina. The other ring, which is open, rests outside.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_25_10641=[""].join("\n");
var outline_f10_25_10641=null;
var title_f10_25_10642="Calculator: Stroke Risk in Female Patients 55-84 Years Old (Framingham data)";
var content_f10_25_10642=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"StrokeRiskFramingham_F_form\" name=\"StrokeRiskFramingham_F_form\" onkeydown=\"clrResults();\" onkeyup=\"StrokeRiskFramingham_F_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Stroke Risk in Female Patients 55-84 Years Old (Framingham data)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         RiskFactorDiff = (Age * 0.0657) + (SysBP * 0.0197) - (SysBP * (HTNMed &gt; 0) * 0.0134) + HTNMed + DM + Cig + CVD + AFib + LVH - 7.5766",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         RiskDuringPeriod = 100 * (1 - RiskPeriodFactor",
"         <sup>",
"          e",
"          <sup>",
"           (RiskFactorDiff)",
"          </sup>",
"         </sup>",
"         )",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Age",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Age_param\" onblur=\"StrokeRiskFramingham_F_fx(); minMaxCheck();\" onchange=\"StrokeRiskFramingham_F_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Age_unit\" onchange=\"StrokeRiskFramingham_F_fx();\" style=\"width:105px;\">",
"             <option value=\"0.0833333333333333|0|mo\">",
"              mo",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|yr\">",
"              yr",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Sys BP",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Sys_BP_param\" onblur=\"StrokeRiskFramingham_F_fx(); minMaxCheck();\" onchange=\"StrokeRiskFramingham_F_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Sys_BP_unit\" onchange=\"StrokeRiskFramingham_F_fx();\" style=\"width:105px;\">",
"             <option value=\"0.00750063755419211|0|Pascal\">",
"              Pascal",
"             </option>",
"             <option value=\"760.002100178515|0|atm\">",
"              atm",
"             </option>",
"             <option value=\"750.063755419211|0|bar\">",
"              bar",
"             </option>",
"             <option value=\"0.735561538478802|0|cmH2O\">",
"              cmH2O",
"             </option>",
"             <option value=\"10|0|cmHg\">",
"              cmHg",
"             </option>",
"             <option value=\"22.4199156928339|0|ftH2O\">",
"              ftH2O",
"             </option>",
"             <option value=\"0.735561538478802|0|gm/sqcm\">",
"              gm/sqcm",
"             </option>",
"             <option value=\"1.86832630773616|0|inH2O\">",
"              inH2O",
"             </option>",
"             <option value=\"25.4000840071406|0|inHg\">",
"              inHg",
"             </option>",
"             <option value=\"7.50063755419211|0|kPa\">",
"              kPa",
"             </option>",
"             <option value=\"0.750063755419211|0|mbar\">",
"              mbar",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|mmHg\">",
"              mmHg",
"             </option>",
"             <option value=\"51.7150957831416|0|psi\">",
"              psi",
"             </option>",
"             <option value=\"1|0|torr\">",
"              torr",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             On BP medication",
"            </span>",
"           </td>",
"           <td align=\"left\" colspan=\"2\">",
"            &nbsp;&nbsp;",
"            <select class=\"medCalcFontSelect\" name=\"HTN_Med_pulldown\" onchange=\"StrokeRiskFramingham_F_fx();\" style=\"width:170px;\">",
"             <option value=\"0\">",
"              No (0)",
"             </option>",
"             <option value=\"2.5432\">",
"              Yes (2.5432)",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Diabetes present",
"            </span>",
"           </td>",
"           <td align=\"left\" colspan=\"2\">",
"            &nbsp;&nbsp;",
"            <select class=\"medCalcFontSelect\" name=\"DM_pulldown\" onchange=\"StrokeRiskFramingham_F_fx();\" style=\"width:170px;\">",
"             <option value=\"0\">",
"              No (0)",
"             </option>",
"             <option value=\"0.5442\">",
"              Yes (0.5442)",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Cigarette smoker",
"            </span>",
"           </td>",
"           <td align=\"left\" colspan=\"2\">",
"            &nbsp;&nbsp;",
"            <select class=\"medCalcFontSelect\" name=\"Cig_pulldown\" onchange=\"StrokeRiskFramingham_F_fx();\" style=\"width:170px;\">",
"             <option value=\"0\">",
"              No (0)",
"             </option>",
"             <option value=\"0.5294\">",
"              Yes (0.5294)",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Cardiovascular dx",
"            </span>",
"           </td>",
"           <td align=\"left\" colspan=\"2\">",
"            &nbsp;&nbsp;",
"            <select class=\"medCalcFontSelect\" name=\"CVD_pulldown\" onchange=\"StrokeRiskFramingham_F_fx();\" style=\"width:170px;\">",
"             <option value=\"0\">",
"              No (0)",
"             </option>",
"             <option value=\"0.4326\">",
"              Yes (0.4326)",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Atrial fibrillation",
"            </span>",
"           </td>",
"           <td align=\"left\" colspan=\"2\">",
"            &nbsp;&nbsp;",
"            <select class=\"medCalcFontSelect\" name=\"AFib_pulldown\" onchange=\"StrokeRiskFramingham_F_fx();\" style=\"width:170px;\">",
"             <option value=\"0\">",
"              No (0)",
"             </option>",
"             <option value=\"1.1497\">",
"              Yes (1.1497)",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             LV hypertrophy",
"            </span>",
"           </td>",
"           <td align=\"left\" colspan=\"2\">",
"            &nbsp;&nbsp;",
"            <select class=\"medCalcFontSelect\" name=\"LVH_pulldown\" onchange=\"StrokeRiskFramingham_F_fx();\" style=\"width:170px;\">",
"             <option value=\"0\">",
"              No (0)",
"             </option>",
"             <option value=\"0.8488\">",
"              Yes (0.8488)",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Risk period",
"            </span>",
"           </td>",
"           <td align=\"left\" colspan=\"2\">",
"            &nbsp;&nbsp;",
"            <select class=\"medCalcFontSelect\" name=\"Risk_Period_Factor_pulldown\" onchange=\"StrokeRiskFramingham_F_fx();\" style=\"width:170px;\">",
"             <option value=\"0.9977\">",
"              1 year (0.9977)",
"             </option>",
"             <option value=\"0.9920\">",
"              2 years (0.9920)",
"             </option>",
"             <option value=\"0.9864\">",
"              3 years (0.9864)",
"             </option>",
"             <option value=\"0.9802\">",
"              4 years (0.9802)",
"             </option>",
"             <option value=\"0.9741\">",
"              5 years (0.9741)",
"             </option>",
"             <option value=\"0.9665\">",
"              6 years (0.9665)",
"             </option>",
"             <option value=\"0.9584\">",
"              7 years (0.9584)",
"             </option>",
"             <option value=\"0.9509\">",
"              8 years (0.9509)",
"             </option>",
"             <option value=\"0.9448\">",
"              9 years (0.9448)",
"             </option>",
"             <option selected=\"selected\" value=\"0.9353\">",
"              10 years (0.9353)",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Results:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Risk Factor Diff",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Risk_Factor_Diff_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td align=\"left\">",
"            &nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Risk During Period",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Risk_During_Period_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"Risk_During_Period_unit\" onchange=\"StrokeRiskFramingham_F_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|%\">",
"               %",
"              </option>",
"              <option value=\"100|0|fraction\">",
"               fraction",
"              </option>",
"              <option value=\"100|0|ratio\">",
"               ratio",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"3\">",
"            <span class=\"medCalcFontOneBold\">",
"             Decimal Precision:",
"            </span>",
"            <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"StrokeRiskFramingham_F_fx();\">",
"             <option>",
"              0",
"             </option>",
"             <option>",
"              1",
"             </option>",
"             <option selected=\"selected\">",
"              2",
"             </option>",
"             <option>",
"              3",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOneBold\">",
"     Notes",
"    </span>",
"    <ul class=\"medCalcFontOne\">",
"     <li>",
"      This risk assessment tool is based on the Cox regression model of proportional hazards.",
"     </li>",
"     <li>",
"      It may be applied to women between the ages of 55 and 84 who have had no prior history of stroke.",
"     </li>",
"     <li>",
"      Cardiovascular disease includes coronary disease, heart failure, or claudication.",
"     </li>",
"    </ul>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontRef\">",
"     <b>",
"      References",
"     </b>",
"    </span>",
"    <ol>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study.",
"       <i>",
"        Stroke",
"       </i>",
"       . 1991 Mar;22(3):312-8.",
"      </span>",
"     </li>",
"    </ol>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_25_10642=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function StrokeRiskFramingham_F_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.StrokeRiskFramingham_F_form){",
"",
"",
"doCalc = true;",
"if (Age_param.value.indexOf(',') >= 0){ Age_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Age_unit.options[Age_unit.selectedIndex].value.split('|');",
"Age = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Sys_BP_param.value.indexOf(',') >= 0){ Sys_BP_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Sys_BP_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Sys_BP_unit.options[Sys_BP_unit.selectedIndex].value.split('|');",
"Sys_BP = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"HTN_Med = parseFloat(HTN_Med_pulldown.options[HTN_Med_pulldown.selectedIndex].value);",
"DM = parseFloat(DM_pulldown.options[DM_pulldown.selectedIndex].value);",
"Cig = parseFloat(Cig_pulldown.options[Cig_pulldown.selectedIndex].value);",
"CVD = parseFloat(CVD_pulldown.options[CVD_pulldown.selectedIndex].value);",
"AFib = parseFloat(AFib_pulldown.options[AFib_pulldown.selectedIndex].value);",
"LVH = parseFloat(LVH_pulldown.options[LVH_pulldown.selectedIndex].value);",
"Risk_Period_Factor = parseFloat(Risk_Period_Factor_pulldown.options[Risk_Period_Factor_pulldown.selectedIndex].value);",
"dp = decpts.options[decpts.selectedIndex].text;",
"Risk_Factor_Diff =  (Age * 0.0657) + (Sys_BP * 0.0197) - (Sys_BP * (HTN_Med > 0) * 0.0134) + HTN_Med + DM + Cig + CVD + AFib + LVH - 7.5766;",
"",
"if (doCalc) Risk_Factor_Diff_param.value = fixDP(Risk_Factor_Diff, dp);",
"",
"",
"",
"Risk_During_Period =  100 * (1 - power(Risk_Period_Factor, eTo(Risk_Factor_Diff)));",
"",
"unit_parts = Risk_During_Period_unit.options[Risk_During_Period_unit.selectedIndex].value.split('|');",
"if (doCalc) Risk_During_Period_param.value = fixDP((Risk_During_Period - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.StrokeRiskFramingham_F_form){",
"",
"if (Age_param.value && Age < 55) {",
"Age = 0;",
"Age_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Age is 55 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Age_param.value && Age > 84) {",
"Age_param.value = \"\";",
"clrResults();",
"Age = 0;",
"doCalc = false;",
"alert(\"The maximum value for Age is 84 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.StrokeRiskFramingham_F_form){",
"",
"Risk_Factor_Diff_param.value = '';",
"Risk_During_Period_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"/* ]]> */"].join("\n");
var outline_f10_25_10642=null;
var title_f10_25_10643="Molluscum conjunctivitis";
var content_f10_25_10643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Molluscum contagiosum on the eyelid with conjunctivitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Molluscum contagiosum. Examination also revealed unilateral conjunctivitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tasman, W, Jaeger, E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2nd Edition, Lippincott Williams &amp; Wilkins 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_25_10643=[""].join("\n");
var outline_f10_25_10643=null;
var title_f10_25_10644="Stage I lateral condyle fracture 2";
var content_f10_25_10644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Stage I fracture of the lateral condyle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 597px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A) Anteroposterior radiograph shows 1-mm fracture line. Panel B) Lateral view shows 2 mm of displacement with posterolateral Thurston-Holland fragment. Panels C and D) Anteroposterior and lateral radiographs 4 weeks later show healed fracture with callus formation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Beaty JH, Kasser JR. The elbow: Physeal fractures, apophyseal injuries of the distal humerus, avascular necrosis of the trochlea, and T-condylar fractures. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_25_10644=[""].join("\n");
var outline_f10_25_10644=null;
var title_f10_25_10645="Vaccine effectiveness";
var content_f10_25_10645=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 634px\">",
"   <div class=\"ttl\">",
"    Effectiveness of routine childhood immunizations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 614px; height: 792px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cases of disease except as otherwise indicated for invasive Haemophilus influenza type b disease and invasive pneumococcal disease (see footnote). Blue lines indicate the approximate date of routine childhood immunization against the disease.",
"    <div class=\"footnotes\">",
"     Hib: Haemophilus influenzae type b; PCV7: 7-valent pneumococcal conjugate vaccine.",
"     <br>",
"      * The time period for this graph precedes the measles outbreaks that occurred across the United States during 2008 (see text for details).",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Incidence per 100,000 children under five years of age.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases, 11th ed. Atkinson, W, Wolfe, S, Hamborsky, J, McIntyre, L (Eds). Public Health Foundation, Washington DC 2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_25_10645=[""].join("\n");
var outline_f10_25_10645=null;
var title_f10_25_10646="Treatment and prevention of osteomyelitis following trauma";
var content_f10_25_10646=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of osteomyelitis following trauma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/25/10646/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/25/10646/contributors\">",
"     Steven K Schmitt, MD, FIDSA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/25/10646/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/25/10646/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/25/10646/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/25/10646/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/25/10646/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttraumatic osteomyelitis refers to osteomyelitis that develops as a result of contaminated open fractures or surgical treatment of closed fractures. Posttraumatic osteomyelitis can occur in up to 25 percent of open fractures; the risk depends upon the following factors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10646/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severity of fracture",
"     </li>",
"     <li>",
"      Severity of soft tissue injury",
"     </li>",
"     <li>",
"      Degree of bacterial contamination",
"     </li>",
"     <li>",
"      Presence of underlying vascular insufficiency (eg, peripheral vascular disease or diabetes)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The microbiology, clinical features, diagnosis, and management of osteomyelitis in the setting of contaminated open fractures will be reviewed here. Hematogenous osteomyelitis and prosthetic joint infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42726?source=see_link\">",
"     \"Hematogenous osteomyelitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=see_link\">",
"     \"Treatment of prosthetic joint infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microorganisms can be introduced directly into bone in the setting of trauma or via contiguous spread from injury to overlying soft tissue. They proliferate in the presence of devitalized tissues containing clotted blood and necrotic bone.",
"   </p>",
"   <p>",
"    Posttraumatic osteomyelitis pathogens in adults may include skin flora, soil organisms, or nosocomial pathogens acquired in the hospital before, during, or after surgical intervention. Staphylococcus aureus, coagulase-negative staphylococci, and aerobic gram-negative bacilli are the most common organisms; other pathogens, including enterococci, anaerobes, fungi, and mycobacteria, have also been implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10646/abstract/3,7-13\">",
"     3,7-13",
"    </a>",
"    ]. Similar microbiology is seen is children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10646/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wound infections among combat casualties with tibial fractures have been associated with drug-resistant aerobic gram-negative organisms, including Acinetobacter baumannii and Pseudomonas aeruginosa [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10646/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cultures obtained at the time of initial debridement do not always reflect the pathogens involved once osteomyelitis has developed; the correlation is about 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10646/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hallmarks of posttraumatic osteomyelitis are nonunion of the fracture site and poor wound healing after wound closure. Other symptoms may include fever and local wound drainage, erythema, warmth, swelling, and pain.",
"   </p>",
"   <p>",
"    The tibia is the bone most frequently involved by posttraumatic osteomyelitis, likely because it is the most common site of open fracture given its lack of muscle covering and limited anastomotic blood supply [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10646/abstract/8,19,20\">",
"     8,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing an accurate diagnosis of osteomyelitis is critical, since the infection can require prolonged antibiotic therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aggressive surgical intervention. The diagnosis of osteomyelitis is discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link\">",
"     \"Overview of osteomyelitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=see_link\">",
"     \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Initial fracture management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management of fractures includes thorough irrigation and debridement. Cultures of bone biopsies or fluid collections obtained after superficial debridement of necrotic tissue should be sent for both aerobic and anaerobic culture. Prophylactic antibiotics and tetanus immunization should also be administered promptly [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10646/abstract/21\">",
"     21",
"    </a>",
"    ]. Subsequently, fracture fixation is needed for stabilization and union. Once union is achieved, fixation hardware should be removed (if possible) and additional debridement performed. Final steps include bone grafting (if needed) and wound closure once the soft tissue over the area of bone trauma is fully healed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10646/abstract/22-32\">",
"     22-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic antibiotics should be administered parenterally within six hours after open trauma to reduce the risk of soft tissue infection or osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10646/abstract/19,21,33,34\">",
"     19,21,33,34",
"    </a>",
"    ]. The efficacy of prophylactic antibiotics was demonstrated in a meta-analysis that included 913 patients with open fractures from seven randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10646/abstract/23\">",
"     23",
"    </a>",
"    ]. The use of prophylactic antibiotics was associated with an absolute reduction in infection risk of 0.08 (95% CI 0.04 to 0.12) with a number needed to treat of 13.",
"   </p>",
"   <p>",
"    Data and guidelines addressing the choice of prophylactic antibiotics in open bone fractures largely predate the widespread prevalence of MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10646/abstract/21,35\">",
"     21,35",
"    </a>",
"    ]. Initial empiric parenteral antibiotic therapy should be directed against gram-positive and gram-negative organisms.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     Cefuroxime",
"    </a>",
"    is appropriate for coverage of this spectrum. For patients at risk for methicillin-resistant Staphylococcus aureus, prophylactic antibiotics should include an agent with activity against MRSA such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef53504 \" href=\"UTD.htm?5/9/5275\">",
"     table 1",
"    </a>",
"    ). For patients intolerant of cephalosporins, fluoroquinolones are an alternate class of prophylactic agents with gram-negative activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=see_link\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prophylactic antibiotics should be administered for 48 to 72 hours total or for 24 hours after wound closure. Prolonged administration of prophylactic antibiotics does not reduce the risk of infection and can lead to the development of resistant organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10646/abstract/21,36\">",
"     21,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to systemic antibiotic prophylaxis, antibiotic impregnated polymethyl methacrylate beads (PMMB) may be placed temporarily in and around the fracture site [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10646/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. The beads should be removed within two to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10646/abstract/9,41-47\">",
"     9,41-47",
"    </a>",
"    ]. Antibiotic-impregnated calcium sulfate has been used as a bone substitute and delivery system for antibiotics repairing bony defects in open fractures caused by combat-related blast injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10646/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Established osteomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of established osteomyelitis or infected nonunion after an open fracture requires debridement, bone biopsy culture to identify the causative microorganism(s), fracture fixation (if needed) and antimicrobial therapy tailored to culture and susceptibility results [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10646/abstract/10,49,50\">",
"     10,49,50",
"    </a>",
"    ]. Once union is achieved, fixation hardware should be removed (if possible) and additional debridement performed. Final steps include wound closure once the soft tissue over the area of bone trauma is fully healed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10646/abstract/22-32\">",
"     22-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of localized osteomyelitis, surgical removal of involved bone may be possible without compromising bony stability, while diffuse osteomyelitis requires complete resection of the bone for definitive treatment. To achieve optimal union, antibiotic therapy for treatment of infection may need to be administered with fixation hardware in place. Once union is achieved, fixation hardware can be removed, followed by additional debridement, soft tissue coverage and additional antibiotics in the absence of hardware.",
"   </p>",
"   <p>",
"    If infected hardware must be retained indefinitely, long-term antibiotic suppression is warranted with an oral agent to which the osteomyelitis pathogen is known to be susceptible (after a full course of parenteral therapy has been administered).",
"   </p>",
"   <p>",
"    Antibiotic selection, duration of antibiotic therapy and adjunctive therapies for osteomyelitis are discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of osteomyelitis in adults\", section on 'Treatment'",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Posttraumatic osteomyelitis refers to osteomyelitis that develops as a result of contaminated open fractures or surgical treatment of closed fractures.",
"     </li>",
"     <li>",
"      Posttraumatic osteomyelitis pathogens may include skin flora, soil organisms, or nosocomial pathogens acquired in the setting of surgical intervention. Staphylococcus aureus, coagulase-negative staphylococci, and aerobic gram-negative bacilli are the most common organisms; other pathogens including enterococci, anaerobes, fungi and mycobacteria have also been implicated. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hallmarks of posttraumatic osteomyelitis are nonunion of the fracture site and poor wound healing after wound closure. Other symptoms may include fever and local wound drainage, erythema, warmth swelling and pain. The tibia is the bone most frequently involved by posttraumatic osteomyelitis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of osteomyelitis is discussed in detail separately (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link\">",
"       \"Overview of osteomyelitis in adults\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Initial management of fractures includes thorough irrigation and debridement, cultures of bone biopsies or fluid collections for aerobic and anaerobic culture, and administration of prophylactic antibiotics. Tetanus immunization should also be administered promptly. Subsequent management includes fracture fixation for stabilization and union, bone grafting (if needed) and wound closure once the soft tissue over the area of bone trauma is fully healed. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Initial fracture management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that prophylactic antibiotics be administered parenterally after trauma to reduce the risk of soft tissue infection or osteomyelitis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Antibiotics should generally be given within six hours of trauma. Reasonable regimens for prophylaxis are outlined above. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prophylactic antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of established osteomyelitis or infected nonunion after an open fracture requires debridement, bone biopsy culture to identify the causative microorganism(s), fracture fixation (if needed) and antimicrobial therapy tailored to culture and susceptibility results. Once union is achieved, fixation hardware should be removed (if possible) and additional debridement performed. Final steps include wound closure once the soft tissue over the area of bone trauma is fully healed. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Established osteomyelitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/1\">",
"      Merritt K. Factors increasing the risk of infection in patients with open fractures. J Trauma 1988; 28:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/2\">",
"      DeLong WG Jr, Born CT, Wei SY, et al. Aggressive treatment of 119 open fracture wounds. J Trauma 1999; 46:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/3\">",
"      Gross T, Kaim AH, Regazzoni P, Widmer AF. Current concepts in posttraumatic osteomyelitis: a diagnostic challenge with new imaging options. J Trauma 2002; 52:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/4\">",
"      Patzakis MJ, Wilkins J. Factors influencing infection rate in open fracture wounds. Clin Orthop Relat Res 1989; :36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/5\">",
"      Tsukayama DT. Pathophysiology of posttraumatic osteomyelitis. Clin Orthop Relat Res 1999; :22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/6\">",
"      Lavery LA, Walker SC, Harkless LB, Felder-Johnson K. Infected puncture wounds in diabetic and nondiabetic adults. Diabetes Care 1995; 18:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/7\">",
"      Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004; 364:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/8\">",
"      Khatod M, Botte MJ, Hoyt DB, et al. Outcomes in open tibia fractures: relationship between delay in treatment and infection. J Trauma 2003; 55:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/9\">",
"      Mader JT, Ortiz M, Calhoun JH. Update on the diagnosis and management of osteomyelitis. Clin Podiatr Med Surg 1996; 13:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/10\">",
"      Trampuz A, Zimmerli W. Diagnosis and treatment of infections associated with fracture-fixation devices. Injury 2006; 37 Suppl 2:S59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/11\">",
"      Haas DW, McAndrew MP. Bacterial osteomyelitis in adults: evolving considerations in diagnosis and treatment. Am J Med 1996; 101:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/12\">",
"      Karam GH, Ackley AM, Dismukes WE. Posttraumatic Aeromonas hydrophila osteomyelitis. Arch Intern Med 1983; 143:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/13\">",
"      Lavery LA, Harkless LB, Felder-Johnson K, Mundine S. Bacterial pathogens in infected puncture wounds in adults with diabetes. J Foot Ankle Surg 1994; 33:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/14\">",
"      Laughlin TJ, Armstrong DG, Caporusso J, Lavery LA. Soft tissue and bone infections from puncture wounds in children. West J Med 1997; 166:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/15\">",
"      Harkness B, Andresen D, Kesson A, Isaacs D. Infections following lawnmower and farm machinery-related injuries in children. J Paediatr Child Health 2009; 45:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/16\">",
"      Johnson EN, Burns TC, Hayda RA, et al. Infectious complications of open type III tibial fractures among combat casualties. Clin Infect Dis 2007; 45:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/17\">",
"      Kindsfater K, Jonassen EA. Osteomyelitis in grade II and III open tibia fractures with late debridement. J Orthop Trauma 1995; 9:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/18\">",
"      Lee J. Efficacy of cultures in the management of open fractures. Clin Orthop Relat Res 1997; :71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/19\">",
"      Patzakis MJ, Wilkins J, Moore TM. Considerations in reducing the infection rate in open tibial fractures. Clin Orthop Relat Res 1983; :36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/20\">",
"      Mader JT, Cripps MW, Calhoun JH. Adult posttraumatic osteomyelitis of the tibia. Clin Orthop Relat Res 1999; :14.",
"     </a>",
"    </li>",
"    <li>",
"     Eastern Association for the Surgery of Trauma (EAST) working group. 1998. Practice management guidelines for prophylactic antibiotic use in open fractures. Available online at www.east.org/tpg.html (Accessed March 26, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/22\">",
"      Cierny, G 3d, Mader, JT. Adult chronic osteomyelitis. Orthopedics 1984; 7:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/23\">",
"      Gosselin RA, Roberts I, Gillespie WJ. Antibiotics for preventing infection in open limb fractures. Cochrane Database Syst Rev 2004; :CD003764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/24\">",
"      B&ouml;hm E, Josten C. What's new in exogenous osteomyelitis? Pathol Res Pract 1992; 188:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/25\">",
"      Meadows SE, Zuckerman JD, Koval KJ. Posttraumatic tibial osteomyelitis: diagnosis, classification, and treatment. Bull Hosp Jt Dis 1993; 52:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/26\">",
"      Anthony JP, Mathes SJ, Alpert BS. The muscle flap in the treatment of chronic lower extremity osteomyelitis: results in patients over 5 years after treatment. Plast Reconstr Surg 1991; 88:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/27\">",
"      May, JW, Jupiter, JB, Gallico, GG, et al. Treatment of chronic traumatic bone wounds. Microvascular free tissue transfer: A 13-year experience in 96 patients. Ann Surg 1991; 214:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/28\">",
"      Culliford AT 4th, Spector J, Blank A, et al. The fate of lower extremities with failed free flaps: a single institution's experience over 25 years. Ann Plast Surg 2007; 59:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/29\">",
"      Clifford RP, Beauchamp CG, Kellam JF, et al. Plate fixation of open fractures of the tibia. J Bone Joint Surg Br 1988; 70:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/30\">",
"      Clifford RP, Lyons TJ, Webb JK. Complications of external fixation of open fractures of the tibia. Injury 1987; 18:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/31\">",
"      Chapman MW. The role of intramedullary fixation in open fractures. Clin Orthop Relat Res 1986; :26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/32\">",
"      Etter C, Burri C, Claes L, et al. Treatment by external fixation of open fractures associated with severe soft tissue damage of the leg. Biomechanical principles and clinical experience. Clin Orthop Relat Res 1983; :80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/33\">",
"      Seligson D, Henry SL. Treatment of compound fractures. Am J Surg 1991; 161:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/34\">",
"      Patzakis MJ, Bains RS, Lee J, et al. Prospective, randomized, double-blind study comparing single-agent antibiotic therapy, ciprofloxacin, to combination antibiotic therapy in open fracture wounds. J Orthop Trauma 2000; 14:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/35\">",
"      Hauser CJ, Adams CA Jr, Eachempati SR, Council of the Surgical Infection Society. Surgical Infection Society guideline: prophylactic antibiotic use in open fractures: an evidence-based guideline. Surg Infect (Larchmt) 2006; 7:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/36\">",
"      Dellinger EP, Caplan ES, Weaver LD, et al. Duration of preventive antibiotic administration for open extremity fractures. Arch Surg 1988; 123:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/37\">",
"      Ostermann PA, Henry SL, Seligson D. The role of local antibiotic therapy in the management of compound fractures. Clin Orthop Relat Res 1993; :102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/38\">",
"      Ostermann PA, Seligson D, Henry SL. Local antibiotic therapy for severe open fractures. A review of 1085 consecutive cases. J Bone Joint Surg Br 1995; 77:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/39\">",
"      Henry SL, Ostermann PA, Seligson D. The prophylactic use of antibiotic impregnated beads in open fractures. J Trauma 1990; 30:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/40\">",
"      Worlock P, Slack R, Harvey L, Mawhinney R. The prevention of infection in open fractures. An experimental study of the effect of antibiotic therapy. J Bone Joint Surg Am 1988; 70:1341.",
"     </a>",
"    </li>",
"    <li>",
"     Cierny, G 3d, Mader, JT. The surgical treatment of adult osteomyelitis. In: Surgery of the Musculoskeletal System, Evarts, CM (Ed), Churchill Livingstone, New York 1983. p.15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/42\">",
"      Adams K, Couch L, Cierny G, et al. In vitro and in vivo evaluation of antibiotic diffusion from antibiotic-impregnated polymethylmethacrylate beads. Clin Orthop Relat Res 1992; :244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/43\">",
"      Calhoun JH, Mader JT. Antibiotic beads in the management of surgical infections. Am J Surg 1989; 157:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/44\">",
"      Henry SL, Seligson D, Mangino P, Popham GJ. Antibiotic-impregnated beads. Part I: Bead implantation versus systemic therapy. Orthop Rev 1991; 20:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/45\">",
"      Popham GJ, Mangino P, Seligson D, Henry SL. Antibiotic-impregnated beads. Part II: Factors in antibiotic selection. Orthop Rev 1991; 20:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/46\">",
"      Scott DM, Rotschafer JC, Behrens F. Use of vancomycin and tobramycin polymethylmethacrylate impregnated beads in the management of chronic osteomyelitis. Drug Intell Clin Pharm 1988; 22:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/47\">",
"      Wilson KJ, Cierny G, Adams KR, Mader JT. Comparative evaluation of the diffusion of tobramycin and cefotaxime out of antibiotic-impregnated polymethylmethacrylate beads. J Orthop Res 1988; 6:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/48\">",
"      Helgeson MD, Potter BK, Tucker CJ, et al. Antibiotic-impregnated calcium sulfate use in combat-related open fractures. Orthopedics 2009; 32:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/49\">",
"      Weber EJ. Plantar puncture wounds: a survey to determine the incidence of infection. J Accid Emerg Med 1996; 13:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10646/abstract/50\">",
"      Roesgen M, Hierholzer G, Hax PM. Post-traumatic osteomyelitis. Pathophysiology and management. Arch Orthop Trauma Surg 1989; 108:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7659 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-A93D27A9D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_25_10646=[""].join("\n");
var outline_f10_25_10646=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Initial fracture management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Established osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7659\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7659|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/9/5275\" title=\"table 1\">",
"      Risk factors for MRSA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=related_link\">",
"      Approach to imaging modalities in the setting of suspected osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42726?source=related_link\">",
"      Hematogenous osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=related_link\">",
"      Treatment of prosthetic joint infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_25_10647="Overview and clinical assessment of the complement system";
var content_f10_25_10647=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview and clinical assessment of the complement system",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/25/10647/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/25/10647/contributors\">",
"     M Kathryn Liszewski, BA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/25/10647/contributors\">",
"     John P Atkinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/25/10647/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/25/10647/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/25/10647/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/25/10647/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/25/10647/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/25/10647/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complement system is a major component of innate immunity and a complement (from whence its name is derived) to antibody-triggered responses [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10647/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It consists of plasma and membrane proteins, which mediate several pathways of cascading enzymatic reactions. Activation of these pathways results in the deposition of complement fragments on pathologic targets and the liberation of fragments that promote inflammatory and immune responses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=see_link\">",
"     \"Complement pathways\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the early steps, an amplification process occurs as components are activated by proteolysis. Complement activation is proinflammatory and thus may be deleterious to host tissue. As a result, nearly one-half of the complement proteins function to regulate the system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=see_link\">",
"     \"Regulators and receptors of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Pathways and activating conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three major divisions or pathways of the complement system are recognized: the classical, alternative, and lectin pathways (",
"    <a class=\"graphic graphic_figure graphicRef56374 \" href=\"UTD.htm?34/46/35566\">",
"     figure 1",
"    </a>",
"    ). These divisions are activated by different means:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The classical pathway is engaged when IgM or IgG antibodies bind to antigens (such as viruses, bacteria, or autoantigens). IgG subclasses 1 and 3 efficiently fix complement, while IgG4 does not. IgG2 fixes complement, although less well than IgG1 or IgG3.",
"     </li>",
"     <li>",
"      The activation scheme of the lectin pathway is similar to the classical pathway except that antibody is replaced by a lectin, such as mannose-binding protein (MBP, also called mannan-binding lectin or MBL). Lectins bind to repetitive sugar patterns on the surface of a pathogen. These lectins are associated with serine proteases (MBL associated serine proteases or MASPs) that are structurally and functionally similar to the classical pathway subcomponents of C1: C1r and C1s. The MASPs also activate by proteolytic cleavage of C2 and C4 (analogous to C1s).",
"     </li>",
"     <li>",
"      The alternative pathway is an ancient surveillance system that does not require the presence of antibodies or lectins to become activated. It is continuously turning over (so called \"tickover\") at a low level. If activated C3 binds to target, it can amplify using the alternative pathway's feedback loop mechanism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Functions of the complement system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major goal of all three complement pathways is the deposition of the complement fragment C3b on the target. This marks the target for immune adherence and ingestion by phagocytic cells. In addition, C3b is the nidus for amplification as noted above and the gateway to the membrane attack complex (MAC).",
"   </p>",
"   <p>",
"    Each pathway also leads to the release of anaphylatoxins (C3a, C4a, C5a) and commonly, to the assembly of the membrane attack complex.",
"   </p>",
"   <p>",
"    In pathologic conditions featuring autoantibodies and immune complexes, complement activation contributes to cell and tissue damage. In acute injury states (membrane damage, apoptosis, necrosis) and with deposition of debris (lipids, proteins, pigments, crystals), the system plays an important role in the host's response to such altered self.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EFFECTS OF ACTIVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upon activation, the complement system modifies membranes and promotes the inflammatory response:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Membrane modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complement fragments may deposit in large numbers on microbes and unwanted materials (such as immune aggregates, apoptotic cells and necrotic tissue). In less than five minutes, for example, several million C3b fragments may be deposited on a bacterium. This coating or \"opsonization\" of bacteria allows specific receptors on peripheral blood cells (especially phagocytes) to bind these ligands. In addition, activation of complement results in the formation of the membrane attack complex (MAC). This complex perturbs the bacterial cell membrane, and in organisms such as gram negative bacteria, results in lysis of the microbe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Promotion of inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activation of the complement system leads to the release of peptides that are potent mediators of inflammatory and immune responses. These fragments, known as \"anaphylatoxins,\" bind to their respective receptors on cells to initiate inflammation and activate immune cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10647/abstract/3\">",
"     3",
"    </a>",
"    ]. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Directed movement of motile cells to an inflammatory site (chemotaxis and chemokinesis)",
"     </li>",
"     <li>",
"      Release of mediators, such as histamine from mast cells",
"     </li>",
"     <li>",
"      Activation of many cell types, including epithelial and endothelial cells as well as most players in the inflammatory and immune responses",
"     </li>",
"     <li>",
"      Contraction of smooth muscles",
"     </li>",
"     <li>",
"      Dilation of blood vessels",
"     </li>",
"     <li>",
"      Exudation of plasma and cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A development in the anaphylatoxin field is the discovery that C3a and C4a (although not C5a) have direct antimicrobial activity, and that this property has been preserved throughout vertebrate evolution [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10647/abstract/4\">",
"     4",
"    </a>",
"    ]. This finding provides an additional mechanism through which complement can kill microorganisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NOMENCLATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although complement was initially recognized as \"a lytic substance\" in the 1880s, the biochemical complexity of the system was not appreciated until the 1960s and 1970s. Components were named as they were identified, leading to some inconsistencies in terminology.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Components of the classical pathway are designated by the capital letter C combined with a number, eg, C1, C2, C3, and C4. This scheme is also used for components of the membrane attack complex, eg, C5, C6, C7, C8, and C9. The numbers are in order of reactivity except that C4 is activated before C3 in the classical and lectin pathways.",
"     </li>",
"     <li>",
"      Alternative pathway components are designated as factors, such as factor B and factor D.",
"     </li>",
"     <li>",
"      Upon proteolytic activation, a liberated smaller fragment is designated by a small letter (such as C3a or Ba). The larger fragment attaches to a target and is then listed with a \"b,\" as in C3b or Bb.",
"     </li>",
"     <li>",
"      Inactivation by limited proteolysis produces further breakdown products designated with suffixes; for example, C3c and C3d are produced when C3b is cleaved.",
"     </li>",
"     <li>",
"      Receptors and regulators are defined by their function (eg,",
"      <span class=\"nowrap\">",
"       C3b/C4b",
"      </span>",
"      receptor, C1 inhibitor, etc), order of discovery, or ligand (eg, complement receptor type 1 [CR1], the immune adherence receptor).",
"     </li>",
"     <li>",
"      The membrane receptors and regulators are present on hematopoietic cells, and therefore, have been given \"cluster of differentiation\" (CD) assignments (eg, the designation of CR1 as CD35).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     COMPLEMENT MEASUREMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complement levels are evaluated by antigenic and functional assays [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10647/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The most frequently used are immunoassays for C3 and C4 and the total hemolytic complement (THC or CH50).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     CH50",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CH50 assesses the ability of serum to lyse sheep erythrocytes optimally sensitized with rabbit IgM antibody. All nine components of the classical pathway (C1 through C9) are required to give a normal CH50. A normal CH50 value ranges from 150 to 250",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    in a commonly employed assay system, and the titer is the reciprocal of the dilution of serum required to lyse 50 percent of the antibody-coated sheep erythrocytes. As an example, a CH50 titer of 200 units means that the test serum lysed 50 percent when used at a dilution of 1:200.",
"   </p>",
"   <p>",
"    CH50 is a useful screening tool for detecting a deficiency of the classical pathway, either of an inherited deficiency of a single component or of several components due to activation of a pathway.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A homozygous deficiency of a classical pathway component is indicated by an extremely low CH50 value of &le;10",
"      <span class=\"nowrap\">",
"       units/mL.",
"      </span>",
"     </li>",
"     <li>",
"      Activation of complement during an inflammatory process (as may be seen in SLE) reduces the CH50 less dramatically. In this setting, the CH50 is rarely &lt;10",
"      <span class=\"nowrap\">",
"       units/mL.",
"      </span>",
"      C3 and C4 are often depressed as well in this setting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The CH50 assay requires appropriate collection, processing, and storage of specimens since several complement proteins are unstable. As a result, a common cause of a depressed CH50 is improper specimen handling. Serum samples should be assayed the day of collection or immediately frozen at -70&ordm;C for subsequent analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     AH50",
"    </span>",
"    &nbsp;&mdash;&nbsp;A measure of the total alternative pathway is the AH50. This assay is similar to the CH50, but measures lysis of unsensitized rabbit red blood cells under conditions that allow only alternative pathway activation. It is not widely available, but can be performed in referral laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Serum C3 and C4 levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma C3 and C4 levels are usually measured by nephelometric immunoassays. These assays measure changes in the intensity of light scatter as a complement protein interacts with specific antibodies. C3 and C4 levels are helpful in following some patients with SLE, for example, who may have initially depressed levels that improve with treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are also assays for the activation or cleavage fragments of components, such as the anaphylatoxins, C5a and C3a, or fragments such as C3d and Bb. Increased levels reflect ongoing activation of the complement system.",
"     </li>",
"     <li>",
"      Specialized laboratories can evaluate functional and antigenic levels of each of the complement components.",
"     </li>",
"     <li>",
"      Immunofluorescence staining for complement components can be used to assess tissue deposition, such as for C1q, C4, and C3 in a kidney biopsy specimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL SIGNIFICANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complement activation accompanies many infectious and inflammatory processes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Elevated complement levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complement levels may increase up to approximately 50 percent of baseline values as part of the acute phase response. This is an expected part of the host&rsquo;s response to infection and injury.",
"   </p>",
"   <p>",
"    Cytokines such as IL-1, IL-6, and TNF, typically released at sites of inflammation, travel via the circulation to the liver where they increase hepatic synthesis of complement proteins. Chronically very high C3 levels, up to five times baseline, have been reported (rarely) in hematopoietic malignancies and in a case of mixed cryoglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10647/abstract/8\">",
"     8",
"    </a>",
"    ]. In the typical situation, resolution of the inflammation or removal of a tumor will promptly lead to the values returning to baseline. High levels do not lead, in themselves, to tissue damage as the proteins are not in their activated state.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link&amp;anchor=H1#H1\">",
"     \"Acute phase reactants\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Reduced complement levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reduction in serum complement levels is often informative. Any disease associated with circulating immune complexes or autoantibodies of the IgG or IgM class may cause acquired hypocomplementemia. Measurement of complement can be helpful in both the diagnosis and monitoring of certain diseases. In addition, inherited complement deficiencies predispose to the development of autoimmune syndromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link\">",
"     \"Inherited disorders of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurement of complement may be useful in the diagnosis of the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conditions featuring immune complexes, such as SLE, Sj&ouml;gren&rsquo;s syndrome, anticardiolipin syndrome, mixed cryoglobulinemia, serum sickness, and some forms of vasculitis and glomerulonephritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29542?source=see_link\">",
"       \"Acquired disorders of the complement system\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cold agglutinins, in which C3 fragments are present on the surface of red blood cells, and occasionally other autoimmune hemolytic anemias. Serum complement levels may also be low in Evan's syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30535?source=see_link\">",
"       \"Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recurrent infections, especially repeated bacterial infections, in individuals with a normal white blood cell count and normal gamma globulin levels, and the absence of a predisposing illness or immunosuppression. CH50 is a reasonable initial screening test in this setting, although it does not measure the alternative pathway. If the patient has a Neisseria infection and the CH50 is normal, an AH50 is indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After the decision has been made to assess the complement system, the next issue is deciding which tests to order. See the summary of the role of complement in pathologic conditions in the table (",
"    <a class=\"graphic graphic_table graphicRef50281 \" href=\"UTD.htm?33/20/34124\">",
"     table 1",
"    </a>",
"    ). The indications for specific complement assays are presented below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Inherited complement deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A genetic deficiency of a single component is indicated by the fixed absence (ie, in most cases no protein is detectable) of a single component and normal levels of all other complement components [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10647/abstract/1,2,5-7,9,10\">",
"     1,2,5-7,9,10",
"    </a>",
"    ]. The parents should be heterozygotes and have approximately 50 percent of normal levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link\">",
"     \"Inherited disorders of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Acquired complement disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;If multiple components are decreased, the most likely explanation is complement consumption. This pattern is typically seen in acquired disorders of complement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29542?source=see_link\">",
"     \"Acquired disorders of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Measurement of total complement function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolytic assays of total complement function have been a cornerstone of complement measurement for more than 50 years. They provide a useful screening tool, especially if investigating a possible complement deficiency. The CH50 and AH50 (see",
"    <a class=\"local\" href=\"#H9\">",
"     'CH50'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'AH50'",
"    </a>",
"    above) measure the activity of the classical pathway and the alternative pathway, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Measurement of individual components",
"    </span>",
"    &nbsp;&mdash;&nbsp;The measurement of individual complement components can assist in the diagnosis of certain diseases, especially SLE, as well as in monitoring the course of the disease. For example, low C4 and C3 are helpful in establishing the diagnosis of SLE, and changes in C4 and C3 may be valuable in following the course of SLE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\", section on 'Determination of disease activity and severity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Decreased levels of individual components may result either from in vivo consumption (in which there are variable reductions in multiple complement components) or from an inherited component deficiency (in which there is fixed absence of a",
"    <strong>",
"     single",
"    </strong>",
"    complement component).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PATTERNS ASSOCIATED WITH ACTIVATION OF SPECIFIC PATHWAYS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11396743\">",
"    <span class=\"h2\">",
"     Classical pathway activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classical pathway activation is usually indicated by low levels of C4 and C3, and normal levels of factor B. Another pattern seen with classical pathway activation is low C4 and normal C3.",
"   </p>",
"   <p>",
"    There are three explanations for how levels of C4 can be low in the setting of normal C3:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum C3 is normally 5 to 10 times higher than C4, so classical pathway activation may lower the C4 out of the normal range, while the reduced amount of C3 remains within normal limits. The clinician is unlikely to recognize this point initially since a patient&rsquo;s predisease C3 concentration is usually unknown. To illustrate, a SLE patient could have a predisease C3 level of 150",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      which drops to 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      at clinical onset of disease. Thus, C3 remains in the &ldquo;normal range,&rdquo; despite considerable C3 consumption.",
"     </li>",
"     <li>",
"      In hereditary angioedema, C1 excessively cleaves C4 and C2 in plasma because of a deficiency of the C1 inhibitor. However, a C3 convertase doesn&rsquo;t form efficiently in plasma (fluid phase) because the complement system is designed to work on a biologic membrane. Thus, patients with hereditary angioedema have very low C4 but normal C3. A similar phenomenon may occur in syndromes involving excessive soluble immune complexes, such as mixed cryoglobulinemia, SLE, and membranoproliferative glomerulonephritis. Here, the C3 convertase would form on a soluble immune complex and this is inefficient.",
"     </li>",
"     <li>",
"      The third mechanism by which C4 can be reduced in the setting of normal C3 is genetic deficiency of C4. This is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link&amp;anchor=H8#H8\">",
"       \"Inherited disorders of the complement system\", section on 'C4 deficiency'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therefore, the finding of low C4 and normal C3 should prompt consideration of SLE, mixed cryoglobulinemia, membranoproliferative glomerulonephritis types I and III, and hereditary angioedema. The combination of a low C4, normal C3, and a positive test for cryoglobulins should prompt further investigation for the presence of hepatitis B and C. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\", section on 'Laboratory testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=see_link\">",
"     \"Hereditary angioedema: Pathogenesis and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11396752\">",
"    <span class=\"h2\">",
"     Alternative pathway activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative pathway activation is indicated by decreased factor B and C3, and normal levels of C4.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11396760\">",
"    <span class=\"h2\">",
"     Activation of both pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activation of both the classical and alternative pathways is indicated by decreased levels of early components of each pathway, namely C4 and factor B.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF COMPLEMENT COMPONENT SPLIT PRODUCTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of proteolytically derived complement component fragments (split products) is not affected by the acute phase response since they are only produced by complement activation. In addition, although measurement of serum levels is a common and time-honored way of monitoring patients, measurement of the split products of C3, C5, C2, and factor B also can be useful since they appear to be more sensitive markers for",
"    <strong>",
"     in vivo",
"    </strong>",
"    complement activation. They can be helpful in the setting of normal or persistently low static levels. These assays, however, are less commonly available and are more expensive. Instability of the fragments both in vivo and in vitro and activation of complement in collected serum and plasma samples are also obstacles to their widespread use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     OTHER MEASUREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional assays of complement include the measurement of \"non-gamma\" or C3 \"Coombs\" antiglobulin tests and the detection of complement deposition in tissue.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of C3 fragments on erythrocytes in hemolytic anemias can be assessed by agglutination of the erythrocytes with antibodies to C3. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link\">",
"       \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of C1q, C4, C3, factor B, or any other complement protein can be assessed using specific antibodies. This is most commonly performed on kidney and skin biopsies. Deposition of C1q and C4b in tissues supports activation of the classical pathway.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     COMPLEMENT-BASED THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because complement can mediate cell and tissue injury in autoimmune syndromes, it has been a longstanding goal to harness complement inhibitors to prevent undesirable activation. Interest in the complement system has undergone a renaissance over the past decade and the search for inhibitors has intensified [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10647/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=see_link\">",
"     \"Regulators and receptors of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A monoclonal antibody to C5,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"       eculizumab",
"      </a>",
"      , has been shown to inhibit complement mediated hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH) and is approved for treatment of this condition [",
"      <a class=\"abstract\" href=\"UTD.htm?10/25/10647/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. Also, most patients with atypical hemolytic uremic syndrome (aHUS) are haploinsufficient for a complement regulator leading to excessive alternative pathway activation. The monoclonal antibody to C5 is also approved to treat this disease. Theoretically, this agent could be efficacious in any humoral antibody syndrome in which complement is activated and C5a or the membrane attack complex mediates tissue damage. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17082?source=see_link\">",
"       \"Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43849?source=see_link&amp;anchor=H181861875#H181861875\">",
"       \"Atypical hemolytic uremic syndrome in children\", section on 'Eculizumab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      C1 inhibitor replacement: Recombinant and serum-derived preparations of C1-inhibitor are in the market place to treat hereditary angioedema (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=see_link\">",
"       \"Hereditary angioedema: Treatment of acute attacks\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Organs from transgenic pigs, which can be made to express human complement regulatory proteins, are relatively resistant to hyperacute rejection mediated by complement when transplanted into primates (xenotransplantation). This experimental technology may someday allow for xenotransplantation of various organs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13912?source=see_link\">",
"       \"Xenotransplantation and the kidney\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complement system is important in the defense of host against microbes, particularly bacteria. It also serves as a mechanism to identify and clear injured tissue and cellular debris. Thus, it is a major player in innate immunity and an effector arm of the humoral immune system. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The three well recognized divisions of the complement system are the classical, alternative, and lectin (",
"      <a class=\"graphic graphic_figure graphicRef56374 \" href=\"UTD.htm?34/46/35566\">",
"       figure 1",
"      </a>",
"      ). Each pathway is activated by a different mechanism. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathways and activating conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major goal of all three cascades is the deposition of large quantities of C3b on a target (opsonization), which marks it for elimination. Engagement of each pathway also leads to the release of proinflammatory anaphylatoxins (C3a, C4a, C5a) and assembly of the membrane attack complex. C3a may have direct microbicidal properties. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Effects of activation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complement levels can be evaluated either by antigenic or functional assays. The CH50 is a functional assay that requires all nine components of the classical pathway (C1 through C9) for a normal result. A homozygous deficiency of classical pathway components is indicated by an extremely low CH50 value (&le;10",
"      <span class=\"nowrap\">",
"       units/mL).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Complement measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In pathologic conditions featuring autoantibodies and immune complexes, complement activation contributes to cell and tissue damage. In acute injury states (membrane damage, apoptosis, necrosis) and with deposition of debris (lipids, proteins, pigments, crystals), the system plays an important role in the host's response to altered self. Failure of this clearance role predisposes to autoimmunity, particularly SLE. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical significance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antigenic levels of C3 and C4 are often depressed in immune-complex mediated diseases, such as SLE. Their assessment can be beneficial in diagnosis and serve as a guide to therapy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Reduced complement levels'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10647/abstract/1\">",
"      Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10647/abstract/2\">",
"      Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10647/abstract/3\">",
"      Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol 2004; 4:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10647/abstract/4\">",
"      Pasupuleti M, Walse B, Nordahl EA, et al. Preservation of antimicrobial properties of complement peptide C3a, from invertebrates to humans. J Biol Chem 2007; 282:2520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10647/abstract/5\">",
"      Ahmed AE, Peter JB. Clinical utility of complement assessment. Clin Diagn Lab Immunol 1995; 2:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10647/abstract/6\">",
"      Wen L, Atkinson JP, Giclas PC. Clinical and laboratory evaluation of complement deficiency. J Allergy Clin Immunol 2004; 113:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10647/abstract/7\">",
"      Glovsky MM, Ward PA, Johnson KJ. Complement determinations in human disease. Ann Allergy Asthma Immunol 2004; 93:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10647/abstract/8\">",
"      Veetil BM, Osborn TG, Mayer DF. Extreme hypercomplementemia in the setting of mixed cryoglobulinemia. Clin Rheumatol 2011; 30:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10647/abstract/9\">",
"      Botto M, Kirschfink M, Macor P, et al. Complement in human diseases: Lessons from complement deficiencies. Mol Immunol 2009; 46:2774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10647/abstract/10\">",
"      Garred P, Honor&eacute; C, Ma YJ, et al. MBL2, FCN1, FCN2 and FCN3-The genes behind the initiation of the lectin pathway of complement. Mol Immunol 2009; 46:2737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10647/abstract/11\">",
"      Wagner E, Frank MM. Therapeutic potential of complement modulation. Nat Rev Drug Discov 2010; 9:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10647/abstract/12\">",
"      Liszewski MK, Farries TC, Lublin DM, et al. Control of the complement system. Adv Immunol 1996; 61:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10647/abstract/13\">",
"      Moore FD Jr. Therapeutic regulation of the complement system in acute injury states. Adv Immunol 1994; 56:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10647/abstract/14\">",
"      Kirschfink M. Targeting complement in therapy. Immunol Rev 2001; 180:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10647/abstract/15\">",
"      Holers VM. The complement system as a therapeutic target in autoimmunity. Clin Immunol 2003; 107:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10647/abstract/16\">",
"      Hill A, Hillmen P, Richards SJ, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 2005; 106:2559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10647/abstract/17\">",
"      Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355:1233.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3920 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-D31E40A6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_25_10647=[""].join("\n");
var outline_f10_25_10647=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Pathways and activating conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Functions of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EFFECTS OF ACTIVATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Membrane modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Promotion of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NOMENCLATURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      COMPLEMENT MEASUREMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CH50",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      AH50",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Serum C3 and C4 levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL SIGNIFICANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Elevated complement levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Reduced complement levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Inherited complement deficiencies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Acquired complement disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Measurement of total complement function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Measurement of individual components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PATTERNS ASSOCIATED WITH ACTIVATION OF SPECIFIC PATHWAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11396743\">",
"      Classical pathway activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11396752\">",
"      Alternative pathway activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11396760\">",
"      Activation of both pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MEASUREMENT OF COMPLEMENT COMPONENT SPLIT PRODUCTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      OTHER MEASUREMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      COMPLEMENT-BASED THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3920\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3920|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/46/35566\" title=\"figure 1\">",
"      Complement pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3920|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/20/34124\" title=\"table 1\">",
"      Complement and disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29542?source=related_link\">",
"      Acquired disorders of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43849?source=related_link\">",
"      Atypical hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=related_link\">",
"      Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=related_link\">",
"      Complement pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17082?source=related_link\">",
"      Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=related_link\">",
"      Hereditary angioedema: Pathogenesis and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=related_link\">",
"      Hereditary angioedema: Treatment of acute attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=related_link\">",
"      Inherited disorders of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30535?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=related_link\">",
"      Regulators and receptors of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13912?source=related_link\">",
"      Xenotransplantation and the kidney",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_25_10648="Liver flukes: Clonorchiasis and opisthorchiasis";
var content_f10_25_10648=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Liver flukes: Clonorchiasis and opisthorchiasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/25/10648/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/25/10648/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/25/10648/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/25/10648/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/25/10648/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/25/10648/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/25/10648/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/25/10648/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three major liver trematodes (flukes) that infect humans are Clonorchis sinensis, Opisthorchis species, and Fasciola hepatica. Clonorchiasis, opisthorchiasis, and the North American liver fluke, Metorchis conjunctus, will be reviewed here. Fascioliasis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31735?source=see_link\">",
"     \"Liver flukes: Fascioliasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLONORCHIS SINENSIS AND OPISTHORCHIS SPECIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clonorchis sinensis (or Opisthorchis sinensis), also known as the Chinese liver fluke, is endemic in the Far East, particularly in China, Japan, Taiwan, Vietnam, and Korea; it is also endemic in far eastern Russia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Clonorchis is a parasite of fish-eating mammals; dogs and cats are the most common reservoirs. It is estimated that more than 35 million people are infected worldwide, with 600 million at risk [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/3\">",
"     3",
"    </a>",
"    ]. Prevalence rates in endemic areas vary widely; in different provinces of China, for example, the prevalence ranges from &lt;1 to 57 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/4\">",
"     4",
"    </a>",
"    ]. One study in Korea noted a prevalence of 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Opisthorchiasis is generally caused by O. felineus or O. viverrini. These are liver flukes of cats, dogs, and other fish-eating mammals, which serve as reservoir hosts. O. felineus occurs in Southeast Asia and in Central and Eastern Europe, particularly in Siberia and other parts of the former Soviet Union. Prevalence rates are 40 to 95 percent in some areas, and it is estimated that more than 16 million people are infected [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/6\">",
"     6",
"    </a>",
"    ]. O. viverrini is endemic in Thailand, Vietnam and Cambodia, and Laos. Prevalence rates of over 24 to 90 percent in villages in Thailand and 40 to 80 percent in Laos have been reported, and it is estimated that worldwide over 23 million people are infected, including 15 million in China [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Adult flukes can remain in the bile ducts for 26 years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/10\">",
"     10",
"    </a>",
"    ]. Protective immunity does not develop and repeat infection can occur, so the cumulative worm burden can increase with age among infected individuals in endemic areas. As a result, symptomatic infection is most common in older adults and may be delayed for many years following initial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/11\">",
"     11",
"    </a>",
"    ]. In endemic areas, the incidence of cholangiocarcinoma is very high. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Chronic symptoms and complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Travelers to or immigrants from endemic areas may harbor the infection and import it to non-endemic areas. Surveys in the United States have suggested that up to 26 percent of Southeast Asian immigrants have an active liver fluke infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In addition, frozen, dried or pickled fish that contain surviving metacercariae can be exported to non-endemic areas, so occasionally infection occurs in individuals who have never traveled to endemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Life cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The life cycles of Clonorchis and Opisthorchis flukes are similar; they begin with release of embryonated eggs into the biliary ducts and subsequently the stool (",
"    <a class=\"graphic graphic_figure graphicRef53219 \" href=\"UTD.htm?28/8/28807\">",
"     figure 1",
"    </a>",
"    ).&nbsp;Eggs are ingested by a snail (first intermediate host), where miracidia are released and go through several developmental stages (sporocysts, rediae, and cercariae).&nbsp;The cercariae are released from the snail into fresh water and subsequently penetrate the flesh of freshwater fish (second intermediate host), where they encyst as metacercariae. Animals (definitive hosts) or humans (incidental hosts) acquire infection via ingestion of raw, undercooked, salted, pickled, or smoked freshwater fish.&nbsp;The metacercariae excyst in the duodenum and ascend the biliary tract.&nbsp;Maturation to adult flukes takes approximately one month. The adults generally reside in small and medium sized biliary ducts; occasionally they reside in the gallbladder or pancreatic duct.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of Opisthorchis and Clonorchis are similar and may be considered together. Most infected individuals are asymptomatic and have a benign course. The risk of symptomatic infection and complications rises as the intensity and duration of infection increase. \"Light\" infections (&lt;100 flukes or up to 10,000 eggs per gram of stool) rarely cause symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Even in heavily infected individuals, symptoms occur in only approximately 10 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Peripheral eosinophilia may be present (usually up to 10 to 20 percent), and serum IgE levels may be elevated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Acute symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathologic and clinical consequences of infection are related to the intensity and duration of cumulative infection. With acute C. sinensis and O. viverrini infection, most infected individuals have low fluke counts and therefore are asymptomatic. Relatively heavy infection occurs in 5 to 10 percent of patients; these individuals have nonspecific symptoms, such as right upper quadrant abdominal pain, indigestion, diarrhea, flatulence, and fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/21\">",
"     21",
"    </a>",
"    ]. With O. felineus infection, acute symptoms are more common, usually beginning 10 to 26 days after eating heavily infected undercooked fish, and manifesting as high-grade fever, anorexia, nausea, vomiting, abdominal pain, malaise, myalgia, arthralgia, malaise, and urticaria [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/22\">",
"     22",
"    </a>",
"    ]. Lymphadenopathy and tender hepatomegaly may be observed.",
"   </p>",
"   <p>",
"    When symptoms occur, they usually last for two to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/8\">",
"     8",
"    </a>",
"    ]. High levels of circulating eosinophils are common. Eggs generally become detectable in the stool after three to four weeks.",
"   </p>",
"   <p>",
"    Some variations in clinical presentations of clonorchiasis and opisthorchiasis may be observed in different geographic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/23\">",
"     23",
"    </a>",
"    ]. For example, O. felineus infection may be associated with an acute, serum sickness-like presentation; C. sinensis infection may be associated with intrahepatic pigment stones [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Chronic symptoms and complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms can occur late in the course of infection due to chronic mechanical injury and physical bile duct obstruction by the adult flukes, particularly in individuals with a heavy burden of adult worms. Symptoms can include fatigue, abdominal discomfort, anorexia, weight loss, dyspepsia, and diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/24\">",
"     24",
"    </a>",
"    ]. An elevated alkaline phosphatase level may be observed, but transaminases are generally normal.",
"   </p>",
"   <p>",
"    The gallbladder is often nonfunctional and enlarged. Dead parasites or ova serve can serve as a nidus for stone formation. Severe disease can result in obstructive jaundice, pancreatitis, recurrent cholangitis, and pyogenic liver abscesses.",
"   </p>",
"   <p>",
"    More serious complications of chronic infection include cholangitis, cholangiohepatitis, and cholangiocarcinoma. These complications result from chronic irritation to epithelial cells, which desquamate and proliferate, eventually leading to hyperplasia, dysplasia, and fibrosis. Periductal eosinophilic and lymphocytic infiltration of portal areas also occurs, suggesting a role for immune-mediated tissue damage. These changes result in formation of pigment stones, biliary strictures, dilation of intrahepatic bile ducts, and fibrosis of hepatic cells. Such complications generally develop after the third decade of life.",
"   </p>",
"   <p>",
"    Patients with heavy Opisthorchis or Clonorchis infections may have a 15-fold higher risk of developing cholangiocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/22\">",
"     22",
"    </a>",
"    ]. Symptoms of cholangiocarcinoma include jaundice, weight loss, epigastric pain, an abdominal mass, and ascites. The mechanisms of carcinogenesis are unclear but may include chronic irritation, nitric oxide formation, intrinsic nitrosation, and activation of drug-metabolizing enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/25\">",
"     25",
"    </a>",
"    ]. The risk appears to be greatest in the setting of O. viverrini infections in Northern Thailand; among such patients, the risk of cholangiocarcinoma is increased 5- to 15-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/4,19\">",
"     4,19",
"    </a>",
"    ]. In one report of 57 patients with cholangiocarcinoma from Hong Kong (where C. sinensis infection is commonly acquired from imported seafood), clonorchiasis was present in 67 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cholangiocarcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis can be established by identifying eggs in stool, duodenal aspirates or bile specimens. Serology has been developed but is not widely available; imaging can be a useful adjunctive diagnostic tool.",
"   </p>",
"   <p>",
"    Diagnosis of clonorchiasis or opisthorchiasis should prompt evaluation of family members with stool microscopy and blood count to evaluate for eosinophilia. In the setting of eosinophilia with negative stool microscopy, ultrasound may be useful. (See",
"    <a class=\"local\" href=\"#H2423396\">",
"     'Other interventions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis can be established by identifying eggs in stool, duodenal aspirates, or bile specimens. Eggs may be visible in the stool approximately four weeks following infection. Eggs may not be present in light infections or may be detectable only in concentrated specimens. It is difficult to distinguish between Clonorchis and Opisthorchis eggs; both are oval in shape and measure approximately 20 to 30 microns by 15 microns (",
"    <a class=\"graphic graphic_picture graphicRef65990 \" href=\"UTD.htm?17/56/18306\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef52742 \" href=\"UTD.htm?5/13/5330\">",
"     picture 2",
"    </a>",
"    ). Differentiation between species is usually based upon geographic exposure or adult fluke morphology.",
"   </p>",
"   <p>",
"    Adult worms may be found at endoscopy or endoscopic retrograde cholangiopancreatography (ERCP). They may also be passed in the stool following anthelminthic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/4,27\">",
"     4,27",
"    </a>",
"    ]. The adult flukes range in size from a few millimeters to several centimeters. The adult C. sinensis worms are flat and elongated, measuring 10 to 25 mm long and 3 to 5 mm wide (",
"    <a class=\"graphic graphic_picture graphicRef76798 \" href=\"UTD.htm?0/61/979\">",
"     picture 3",
"    </a>",
"    ). Adult O. felineus and O. viverrini are usually 8 to 12 mm long, but O. felineus tends to be wider (2 to 3 mm compared with 1 to 2 mm) (",
"    <a class=\"graphic graphic_picture graphicRef64159 \" href=\"UTD.htm?19/58/20386\">",
"     picture 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42087?source=see_link\">",
"     \"Endoscopic diagnosis and management of biliary parasitosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3133749\">",
"    <span class=\"h3\">",
"     Laboratory assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic testing for opisthorchiasis and clonorchiasis using an enzyme-linked immunosorbent assay (ELISA) is performed in some laboratories but is not widely available [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/28-32\">",
"     28-32",
"    </a>",
"    ]. The assay cannot reliably distinguish between current and past infection and also may cross-react with other parasitic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Development of more sensitive and specific assays is under investigation, but, thus far, these are not widely available. One monoclonal antibody based dot-ELISA has been developed using purified O. viverrini antigen; excellent sensitivity and specificity have been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/31\">",
"     31",
"    </a>",
"    ]. Immunoblot assays using C. sinensis-specific excretory-secretory antigens have also been developed with variable sensitivity (76 to 92 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polymerase chain reaction (PCR)-based methods for detecting O. viverrini and C. sinensis eggs in stool have been developed, but are not commercially available [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Compared with standard stool microscopy, the sensitivity of the PCR was found to be 100 percent, 68 percent, and 50 percent in specimens containing &gt;1000, 200 to 1000, and &lt;200 eggs per gram of feces, respectively. Other new methods for diagnosis based on the detection of parasite antigens in stool via dot-blot hybridization techniques are also being developed but are not widely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Useful radiographic tools for diagnosis of clonorchiasis or opisthorchiasis include ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), cholangiography, and ERCP.",
"   </p>",
"   <p>",
"    Ultrasound abnormalities may be observed among both asymptomatic and symptomatic individuals. One study among 123 Korean patients noted that ultrasound abnormalities were observed in 49 percent of individuals with clonorchiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/38\">",
"     38",
"    </a>",
"    ]. Ultrasound findings may include gallbladder enlargement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sludge, bile duct inflammation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibrosis, and hepatomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/39\">",
"     39",
"    </a>",
"    ]. Ultrasound may also detect aggregates of flukes as nonshadowing echogenic foci within bile ducts (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57766 \" href=\"UTD.htm?17/24/17799\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/11\">",
"     11",
"    </a>",
"    ]. In another study of 316 Korean patients with clonorchiasis, four sonographic findings distinguished patients with active disease from controls: increased periductal echogenicity (sensitivity and specificity 35 and 91 percent respectively), floating echogenic foci in the gallbladder (sensitivity and specificity, 28 and 94 percent respectively), diffuse intrahepatic bile ducts dilatation (sensitivity and specificity 67 and 48 percent respectively), and gallbladder distention (sensitivity and specificity 3 and 100 percent respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/40\">",
"     40",
"    </a>",
"    ]. Ultrasound abnormalities often normalize following treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/19\">",
"     19",
"    </a>",
"    ]. In endemic areas the finding of floating echogenic foci in the gallbladder one year after treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    may be suggestive of active clonorchiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For evaluation of relapsing cholangitis, CT scanning has been reported to be more sensitive than ultrasound, since CT can detect the dilated and thickened small intrahepatic bile ducts associated with recurrent pyogenic cholangitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=see_link\">",
"     \"Acute cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MRI can also be a useful diagnostic tool. In one study of 26 Korean patients with clonorchiasis, MRI demonstrated intrahepatic bile duct abnormalities in 89 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/43\">",
"     43",
"    </a>",
"    ]. The distribution of findings included: mild dilation of the intrahepatic bile duct (81 percent), \"too many intrahepatic bile ducts\" (62 percent), wall enhancement and thickening (81 percent), filling defects and ductal stricture in the intrahepatic bile duct (24 and 12 percent, respectively), and extrahepatic ductal dilation (19 percent). Hepatobiliary malignancy was observed in 35 percent of patients.",
"   </p>",
"   <p>",
"    Cholangiography can demonstrate slender filling defects in dilated intrahepatic bile ducts with wall irregularities and tortuosity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42087?source=see_link\">",
"     \"Endoscopic diagnosis and management of biliary parasitosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2423389\">",
"    <span class=\"h3\">",
"     Anthelminthic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of choice for clonorchiasis and opisthorchiasis is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally in three divided doses for two days) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/44\">",
"     44",
"    </a>",
"    ]. Data from small randomized trials have shown that the cure rate for clonorchiasis and opisthorchiasis with this regimen is &gt;90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/8,27,45\">",
"     8,27,45",
"    </a>",
"    ]. Side effects of treatment include headache, dizziness, insomnia, nausea, and vomiting.",
"   </p>",
"   <p>",
"    Lower dose regimens are better tolerated but are less effective for treatment of clonorchiasis. In one study of 21 Vietnamese patients with clonorchiasis treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    (25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for 3 days), the cure rate was only 29 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/46\">",
"     46",
"    </a>",
"    ]. Praziquantel (40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    as a single dose) has been shown to have poor efficacy for clonorchiasis (cure rate 25 percent), although this dose has been shown to be effective for treatment opisthorchiasis (cure rate 91 to 95 percent), and has been used successfully in communities receiving mass treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/8,47-49\">",
"     8,47-49",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Alternatives to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"     mebendazole",
"    </a>",
"    . Albendazole (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally for 7 days) has been associated with good efficacy for clonorchiasis (&gt;90 percent cure rate) and modest efficacy for opisthorchiasis (63 percent cure rate) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/4,49,50\">",
"     4,49,50",
"    </a>",
"    ]. Mebendazole (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for 20 to 30 days) has been associated with cure rates of 89 to 94 percent of opisthorchiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tribendimidine is a new drug under investigation that appears to be at least as efficacious as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    for treatment of opisthorchiasis; further investigation is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical symptoms of infection may take months to resolve, although typically eggs disappear from the stool within a week of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2423396\">",
"    <span class=\"h3\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with heavy, longstanding infection are at risk for complications which may require additional interventions. Management of cholangitis may require antibiotics, biliary drainage,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery; this is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=see_link\">",
"     \"Acute cholangitis\"",
"    </a>",
"    .) Evaluation and management of cholangiocarcinoma is also discussed separately (see related topics).",
"   </p>",
"   <p>",
"    Diagnosis of clonorchiasis or opisthorchiasis should prompt evaluation of family members with stool microscopy. Individuals with evidence of infection should be treated to avoid the risk of future complications, even in the absence of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/8,11\">",
"     8,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection can be prevented by cooking or freezing freshwater fish; strict hygiene measures also decrease transmission. In regions where opisthorchiasis is endemic, mass treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    (single dose) has been shown to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2423389\">",
"     'Anthelminthic therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An opisthorchiasis control program in Thailand is focusing on three main areas: health education about cooking fish adequately, hygiene improvement to prevent water contamination, and stool examination followed by treatment of identified cases to eliminate human host reservoirs [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/56\">",
"     56",
"    </a>",
"    ]. The prevalence of infection in involved regions has been decreasing over time [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     METORCHIS CONJUNCTUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metorchis conjunctus is a liver fluke endemic to North America and Russia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/58\">",
"     58",
"    </a>",
"    ]. It is in the same Opisthorchiidae family as C. sinensis, O. viverrini and O. felineus; all of these organisms have the same life cycle (",
"    <a class=\"graphic graphic_figure graphicRef53219 \" href=\"UTD.htm?28/8/28807\">",
"     figure 1",
"    </a>",
"    ). Many fish-eating mammals (including dogs, fox, seals, and others) can serve as definitive hosts. Aquatic snails serve as the first intermediate host; aquatic fish including the white sucker (Catostomus commersoni) serve as the second intermediate hosts. Humans are incidental hosts.",
"   </p>",
"   <p>",
"    The majority of cases occur among native Canadian populations, and stool surveys in these communities have demonstrated occasional asymptomatic human infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. A small outbreak among 19 Canadian patients in 1993 was caused by sushi prepared with raw white sucker fish [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10648/abstract/61\">",
"     61",
"    </a>",
"    ]. Symptoms (fever, anorexia, epigastric pain, and weight loss)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laboratory abnormalities (elevated liver enzymes in 10 patients; eosinophilia in 15 patients) developed 1 to 15 days following ingestion of the raw fish. Stool microscopy demonstrated opisthorchid eggs among 10 patients; the eggs were indistinguishable from O. viverrini. Symptoms persisted for 3 to 28 days, but responded promptly to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    in all cases. It is unknown whether prolonged infection and biliary complications can occur with M. conjunctus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2424689\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clonorchiasis is caused by Clonorchis sinensis, also known as the Chinese liver fluke, is endemic in the Far East, particularly in China, Japan, Taiwan, Vietnam, and Korea; it is also endemic in far eastern Russia. Opisthorchiasis is caused by O. felineus or O. viverrini. O. felineus occurs in Southeast Asia and in Central and Eastern Europe, particularly in Siberia and other parts of the former Soviet Union. O. viverrini is endemic in Thailand, Kampuchea, and Laos. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The life cycles of Clonorchis and Opisthorchis flukes are similar. Adult worms reside in the bile ducts of the definitive or incidental host; embryonated eggs are released into the biliary ducts and subsequently the stool (",
"      <a class=\"graphic graphic_figure graphicRef53219 \" href=\"UTD.htm?28/8/28807\">",
"       figure 1",
"      </a>",
"      ). Snails and freshwater fish serve as first and second intermediate hosts, respectively. Animals (definitive hosts) or humans (incidental hosts) acquire infection via ingestion of raw, undercooked, salted, pickled, or smoked freshwater fish. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Life cycle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most infected individuals are asymptomatic and have a benign course. The risk of symptomatic infection and complications rises as the intensity and duration of infection increase. When acute symptoms manifest they usually begin 10 to 26 days after consumption of heavily infected undercooked fish and last for two to four weeks. The illness is characterized by fever, anorexia, abdominal pain, myalgia, arthralgia, malaise, and urticaria. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Acute symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms can occur late in the course of infection due to chronic mechanical injury and physical bile duct obstruction by the adult flukes, particularly in individuals with a heavy burden of adult worms. Symptoms can include fatigue, abdominal discomfort, anorexia, weight loss, dyspepsia, and diarrhea. Severe disease can result in obstructive jaundice, pancreatitis, recurrent cholangitis, and pyogenic liver abscesses. More serious complications include cholangitis, cholangiohepatitis, and cholangiocarcinoma. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Chronic symptoms and complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis can be established by identifying eggs in stool, duodenal aspirates, or bile specimens. Eggs may be visible in the stool approximately four weeks following infection. It is difficult to distinguish between Clonorchis and Opisthorchis eggs (",
"      <a class=\"graphic graphic_picture graphicRef52742 \" href=\"UTD.htm?5/13/5330\">",
"       picture 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef65990 \" href=\"UTD.htm?17/56/18306\">",
"       picture 1",
"      </a>",
"      ); differentiation between species is usually based upon geographic exposure or adult fluke morphology. Ultrasound findings may include gallbladder enlargement",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sludge, bile duct inflammation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fibrosis, and hepatomegaly. Ultrasound may also detect aggregates of flukes as nonshadowing echogenic foci within bile ducts. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"       praziquantel",
"      </a>",
"      for treatment of clonorchiasis and opisthorchiasis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Dosing consists of 75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally in three divided doses for two days. Alternatives to praziquantel include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"       albendazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"       mebendazole",
"      </a>",
"      . Clinical symptoms of infection may take months to resolve, although typically eggs disappear from the stool within a week of treatment. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Metorchis conjunctus is a liver fluke endemic to North America and Russia; it has the same life cycle as clonorchiasis and opisthorchiasis (",
"      <a class=\"graphic graphic_figure graphicRef53219 \" href=\"UTD.htm?28/8/28807\">",
"       figure 1",
"      </a>",
"      ). Many fish-eating mammals (including dogs, fox, seals, and others) can serve as definitive hosts. Aquatic fish including the white sucker (Catostomus commersoni) serve as the second intermediate hosts. The majority of cases occur among native Canadian populations. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Metorchis conjunctus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/1\">",
"      Rim HJ. Clonorchiasis: an update. J Helminthol 2005; 79:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/2\">",
"      Wang KX, Zhang RB, Cui YB, et al. Clinical and epidemiological features of patients with clonorchiasis. World J Gastroenterol 2004; 10:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/3\">",
"      Keiser J, Utzinger J. Emerging foodborne trematodiasis. Emerg Infect Dis 2005; 11:1507.",
"     </a>",
"    </li>",
"    <li>",
"     Maclean JD, Cross J, Mahanty S. Liver, lung, and intestinal fluke infections. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 2nd ed, Guerrant RL, Waker DH, Weller PF (Eds), Churchill Livingstone, Philadelphia 2006. p.1349.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/5\">",
"      Kim BJ, Ock MS, Kim IS, Yeo UB. Infection status of Clonorchis sinensis in residents of Hamyang-gun, Gyeongsangnam-do, Korea. Korean J Parasitol 2002; 40:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/6\">",
"      Control of foodborne trematode infections. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1995; 849:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/7\">",
"      Ramasoota T. Current status of food-borne parasitic zoonoses in Thailand. Southeast Asian J Trop Med Public Health 1991; 22 Suppl:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/8\">",
"      Harinasuta T, Pungpak S, Keystone JS. Trematode infections. Opisthorchiasis, clonorchiasis, fascioliasis, and paragonimiasis. Infect Dis Clin North Am 1993; 7:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/9\">",
"      Andrews RH, Sithithaworn P, Petney TN. Opisthorchis viverrini: an underestimated parasite in world health. Trends Parasitol 2008; 24:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/10\">",
"      Tan WB, Shelat VG, Diddapur RK. Oriental liver fluke infestation presenting more than 50 years after immigration. Ann Acad Med Singapore 2009; 38:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/11\">",
"      Liu LX, Harinasuta KT. Liver and intestinal flukes. Gastroenterol Clin North Am 1996; 25:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/12\">",
"      Schwartz DA. Cholangiocarcinoma associated with liver fluke infection: a preventable source of morbidity in Asian immigrants. Am J Gastroenterol 1986; 81:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/13\">",
"      Yossepowitch O, Gotesman T, Assous M, et al. Opisthorchiasis from imported raw fish. Emerg Infect Dis 2004; 10:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/14\">",
"      Morsy AT, Al-Mathal EM. Clonorchis sinensis a new report in Egyptian employees returning back from Saudi Arabia. J Egypt Soc Parasitol 2011; 41:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/15\">",
"      Lewin MR, Weinert MF. An eighty-four-year-old man with fever and painless jaundice: a case report and brief review of Clonorchis sinensis infection. J Travel Med 1999; 6:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/16\">",
"      Chan CW, Lam SK. Diseases caused by liver flukes and cholangiocarcinoma. Baillieres Clin Gastroenterol 1987; 1:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/17\">",
"      Upatham ES, Viyanant V, Kurathong S, et al. Relationship between prevalence and intensity of Opisthorchis viverrini infection, and clinical symptoms and signs in a rural community in north-east Thailand. Bull World Health Organ 1984; 62:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/18\">",
"      Upatham ES, Viyanant V, Kurathong S, et al. Morbidity in relation to intensity of infection in Opisthorchiasis viverrini: study of a community in Khon Kaen, Thailand. Am J Trop Med Hyg 1982; 31:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/19\">",
"      Mairiang E, Haswell-Elkins MR, Mairiang P, et al. Reversal of biliary tract abnormalities associated with Opisthorchis viverrini infection following praziquantel treatment. Trans R Soc Trop Med Hyg 1993; 87:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/20\">",
"      Pungpak S, Harinasuta T, Bunnag D, et al. Fecal egg output in relation to worm burden and clinical features in human opisthorchiasis. Southeast Asian J Trop Med Public Health 1990; 21:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/21\">",
"      Marcos LA, Terashima A, Gotuzzo E. Update on hepatobiliary flukes: fascioliasis, opisthorchiasis and clonorchiasis. Curr Opin Infect Dis 2008; 21:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/22\">",
"      Keiser J, Utzinger J. Food-borne trematodiases. Clin Microbiol Rev 2009; 22:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/23\">",
"      Sithithaworn P, Haswell-Elkins MR, Mairiang P, et al. Parasite-associated morbidity: liver fluke infection and bile duct cancer in northeast Thailand. Int J Parasitol 1994; 24:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/24\">",
"      Pungpak S, Chalermrut K, Harinasuta T, et al. Opisthorchis viverrini infection in Thailand: symptoms and signs of infection--a population-based study. Trans R Soc Trop Med Hyg 1994; 88:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/25\">",
"      Watanapa P, Watanapa WB. Liver fluke-associated cholangiocarcinoma. Br J Surg 2002; 89:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/26\">",
"      Okuda K, Kubo Y, Okazaki N, et al. Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma: a study of 57 autopsy-proven cases. Cancer 1977; 39:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/27\">",
"      Pungpak S, Radomyos P, Radomyos BE, et al. Treatment of Opisthorchis viverrini and intestinal fluke infections with Praziquantel. Southeast Asian J Trop Med Public Health 1998; 29:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/28\">",
"      Sakolvaree Y, Ybanez L, Chaicumpa W. Parasites elicited cross-reacting antibodies to Opisthorchis viverrini. Asian Pac J Allergy Immunol 1997; 15:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/29\">",
"      Akai PS, Pungpak S, Chaicumpa W, et al. Serum antibody responses in opisthorchiasis. Int J Parasitol 1995; 25:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/30\">",
"      Sirisinha S, Chawengkirttikul R, Haswell-Elkins MR, et al. Evaluation of a monoclonal antibody-based enzyme linked immunosorbent assay for the diagnosis of Opisthorchis viverrini infection in an endemic area. Am J Trop Med Hyg 1995; 52:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/31\">",
"      Wongsaroj T, Sakolvaree Y, Chaicumpa W, et al. Affinity purified oval antigen for diagnosis of Opisthorchiasis viverrini. Asian Pac J Allergy Immunol 2001; 19:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/32\">",
"      Lin YL, Chen ER, Yen CM. Antibodies in serum of patients with clonorchiasis before and after treatment. Southeast Asian J Trop Med Public Health 1995; 26:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/33\">",
"      Kim SI. A Clonorchis sinensis-specific antigen that detects active human clonorchiasis. Korean J Parasitol 1998; 36:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/34\">",
"      Li S, Shin JG, Cho PY, et al. Multiple recombinant antigens of Clonorchis sinensis for serodiagnosis of human clonorchiasis. Parasitol Res 2011; 108:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/35\">",
"      Wongratanacheewin S, Pumidonming W, Sermswan RW, et al. Detection of Opisthorchis viverrini in human stool specimens by PCR. J Clin Microbiol 2002; 40:3879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/36\">",
"      Kim EM, Verweij JJ, Jalili A, et al. Detection of Clonorchis sinensis in stool samples using real-time PCR. Ann Trop Med Parasitol 2009; 103:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/37\">",
"      Umesha KR, Kumar S, Parvathi A, et al. Opisthorchis viverrini: detection by polymerase chain reaction (PCR) in human stool samples. Exp Parasitol 2008; 120:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/38\">",
"      Hong ST, Yoon K, Lee M, et al. Control of clonorchiasis by repeated praziquantel treatment and low diagnostic efficacy of sonography. Korean J Parasitol 1998; 36:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/39\">",
"      Elkins DB, Mairiang E, Sithithaworn P, et al. Cross-sectional patterns of hepatobiliary abnormalities and possible precursor conditions of cholangiocarcinoma associated with Opisthorchis viverrini infection in humans. Am J Trop Med Hyg 1996; 55:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/40\">",
"      Choi D, Hong ST, Lim JH, et al. Sonographic findings of active Clonorchis sinensis infection. J Clin Ultrasound 2004; 32:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/41\">",
"      Choi D, Jeon YH, Lee GC, et al. Changes in sonographic findings after treatment of patients with clonorchiasis in a heavy endemic area. Korean J Parasitol 2009; 47:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/42\">",
"      Lim JH. Radiologic findings of clonorchiasis. AJR Am J Roentgenol 1990; 155:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/43\">",
"      Jeong YY, Kang HK, Kim JW, et al. MR imaging findings of clonorchiasis. Korean J Radiol 2004; 5:25.",
"     </a>",
"    </li>",
"    <li>",
"     Drugs for Parasitic Infections, Medical Letter, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/45\">",
"      Jong EC, Wasserheit JN, Johnson RJ, et al. Praziquantel for the treatment of Clonorchis/Opisthorchis infections: report of a double-blind, placebo-controlled trial. J Infect Dis 1985; 152:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/46\">",
"      Tinga N, De N, Vien HV, et al. Little effect of praziquantel or artemisinin on clonorchiasis in Northern Vietnam. A pilot study. Trop Med Int Health 1999; 4:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/47\">",
"      Bunnag D, Harinasuta T. Studies on the chemotherapy of human opisthorchiasis: III. Minimum effective dose of praziquantel. Southeast Asian J Trop Med Public Health 1981; 12:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/48\">",
"      Pungpak S, Bunnag D, Harinasuta T. Clinical and laboratory evaluation of praziquantel in opisthorchiasis. Southeast Asian J Trop Med Public Health 1983; 14:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/49\">",
"      Pungpark S, Bunnag D, Harinasuta T. Albendazole in the treatment of opisthorchiasis and concomitant intestinal helminthic infections. Southeast Asian J Trop Med Public Health 1984; 15:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/50\">",
"      Liu YH, Wang XG, Gao P, Qian MX. Experimental and clinical trial of albendazole in the treatment of Clonorchiasis sinensis. Chin Med J (Engl) 1991; 104:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/51\">",
"      Jaroonvesama N, Charoenlarp K, Cross JH. Treatment of Opisthorchis viverrini with mebendazole. Southeast Asian J Trop Med Public Health 1981; 12:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/52\">",
"      Soukhathammavong P, Odermatt P, Sayasone S, et al. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, tribendimidine, and praziquantel in patients with Opisthorchis viverrini: a randomised, exploratory, open-label, phase 2 trial. Lancet Infect Dis 2011; 11:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/53\">",
"      Qian MB, Yap P, Yang YC, et al. Efficacy and Safety of Tribendimidine Against Clonorchis sinensis. Clin Infect Dis 2013; 56:e76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/54\">",
"      Viravan C, Bunnag D, Harinasuta T, et al. Clinical field trial of praziquantel in opisthorchiasis in Nong Rangya Village, Khon Kaen Province, Thailand. Southeast Asian J Trop Med Public Health 1986; 17:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/55\">",
"      Vivatanasesth P, Sornmani S, Schelp FP, et al. Mass treatment of opisthorchiasis in Northeast Thailand. Southeast Asian J Trop Med Public Health 1982; 13:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/56\">",
"      Jongsuksuntigul P, Imsomboon T. Epidemiology of opisthorchiasis and national control program in Thailand. Southeast Asian J Trop Med Public Health 1998; 29:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/57\">",
"      Jongsuksuntigul P, Imsomboon T. The impact of a decade long opisthorchiasis control program in northeastern Thailand. Southeast Asian J Trop Med Public Health 1997; 28:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/58\">",
"      Mordvinov VA, Yurlova NI, Ogorodova LM, Katokhin AV. Opisthorchis felineus and Metorchis bilis are the main agents of liver fluke infection of humans in Russia. Parasitol Int 2012; 61:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/59\">",
"      Brassard P, Hoey J, Ismail J, Gosselin F. The prevalence of intestinal parasites and enteropathogenic bacteria in James Bay Cree Indians, Quebec. Can J Public Health 1985; 76:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/60\">",
"      Behr MA, Gyorkos TW, Kokoskin E, et al. North American liver fluke (Metorchis conjunctus) in a Canadian aboriginal population: a submerging human pathogen? Can J Public Health 1998; 89:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10648/abstract/61\">",
"      MacLean JD, Arthur JR, Ward BJ, et al. Common-source outbreak of acute infection due to the North American liver fluke Metorchis conjunctus. Lancet 1996; 347:154.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5674 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-F9B63D4400-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_25_10648=[""].join("\n");
var outline_f10_25_10648=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2424689\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLONORCHIS SINENSIS AND OPISTHORCHIS SPECIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Life cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Acute symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Chronic symptoms and complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Microscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3133749\">",
"      - Laboratory assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2423389\">",
"      - Anthelminthic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2423396\">",
"      - Other interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      METORCHIS CONJUNCTUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2424689\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5674\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5674|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/24/17799\" title=\"diagnostic image 1\">",
"      Clonorchiasis sonogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5674|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/8/28807\" title=\"figure 1\">",
"      Liver flukes life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5674|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/56/18306\" title=\"picture 1\">",
"      Clonorchiasis egg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/13/5330\" title=\"picture 2\">",
"      Opisthorchiasis egg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/61/979\" title=\"picture 3\">",
"      Clonorchiasis adult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/58/20386\" title=\"picture 4\">",
"      Opisthorchiasis adult",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=related_link\">",
"      Acute cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40633?source=related_link\">",
"      Clinical manifestations and diagnosis of cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42087?source=related_link\">",
"      Endoscopic diagnosis and management of biliary parasitosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31735?source=related_link\">",
"      Liver flukes: Fascioliasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_25_10649="Clinical features and treatment of uvulitis";
var content_f10_25_10649=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and treatment of uvulitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/25/10649/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/25/10649/contributors\">",
"     Charles R Woods, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/25/10649/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/25/10649/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/25/10649/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/25/10649/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/25/10649/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/25/10649/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uvulitis refers to inflammation of the uvula, which results most commonly from infection or trauma. Acute infection of the uvula should be suspected when the uvula is the most inflamed structure in the posterior pharynx of a febrile patient [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/1\">",
"     1",
"    </a>",
"    ]. Infectious uvulitis usually occurs in the context of pharyngitis; it is uncommon for the uvula to be the only or predominant focus of infection (",
"    <a class=\"graphic graphic_picture graphicRef67939 \" href=\"UTD.htm?31/19/32049\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The epidemiology, etiology, diagnosis, and treatment of uvulitis will be reviewed here. Epiglottitis, pharyngitis, and deep neck space infections are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link\">",
"       \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/16/12553?source=see_link\">",
"       \"Epiglottitis (supraglottitis): Treatment and prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39415?source=see_link\">",
"       \"Evaluation of sore throat in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=see_link\">",
"       \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5738?source=see_link\">",
"       \"Evaluation of acute pharyngitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=see_link\">",
"       \"Retropharyngeal infections in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/61/31705?source=see_link\">",
"       \"Peritonsillar cellulitis and abscess\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=see_link\">",
"       \"Deep neck space infections\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The uvula is an extension of the soft palate. It consists of a vascularized core of smooth muscle and connective tissue surrounded by an epithelial layer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/2\">",
"     2",
"    </a>",
"    ]. The epithelium contains mucous glands and mast cells. The subepithelium contains macrophages and gamma-delta T cells, which appear to form a protective barrier and may account for the relative rarity of uvular infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact incidence of infectious uvulitis is not known. It appears to be uncommon in all age groups, but to occur more frequently among children than adults. Cases reported in adults often are noninfectious (eg, related to trauma, inhalation of irritants, etc) (",
"    <a class=\"graphic graphic_table graphicRef82234 \" href=\"UTD.htm?22/39/23163\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Noninfectious causes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The epidemiology of infectious uvulitis is similar to that of group A streptococcal (GAS,",
"    <em>",
"     Streptococcus pyogenes",
"    </em>",
"    ) infection, which is the most common infectious cause. GAS pharyngitis occurs most frequently among children between 5 and 15 years of age, but it is not isolated to this age group. Cases occur year-round, with a general winter and spring predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\", section on 'Group A streptococcus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uvulitis has infectious and noninfectious causes (",
"    <a class=\"graphic graphic_table graphicRef82234 \" href=\"UTD.htm?22/39/23163\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Infectious causes",
"    </span>",
"   </p>",
"   <p>",
"    Group A streptococcus (GAS) is the most common bacterial cause of uvulitis. GAS uvulitis typically occurs in the context of associated pharyngitis; isolated GAS uvulitis has not been described [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\", section on 'Group A streptococcus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    type b (Hib) is the next most common bacterial cause of uvulitis. Hib uvulitis occurs primarily in regions where infants are not routinely immunized against Hib. Hib uvulitis may occur as an isolated infection or in conjunction with epiglottitis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67878 \" href=\"UTD.htm?22/26/22958\">",
"     image 1",
"    </a>",
"    )",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41608?source=see_link\">",
"     \"Microbiology, epidemiology and treatment of Haemophilus influenzae\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other bacterial causes of uvulitis that have been reported in children",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adults include",
"    <em>",
"     Fusobacterium nucleatum",
"    </em>",
"    ,",
"    <em>",
"     Prevotella intermedia",
"    </em>",
"    , and",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    (with associated epiglottitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. Leprosy (",
"    <em>",
"     Mycobacterium leprae",
"    </em>",
"    ) also can involve the uvula, with manifestations ranging from enanthem-like lesions or ulcerations to fibrosis with partial or complete destruction or loss of the uvula [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <em>",
"     Candida albicans",
"    </em>",
"    uvulitis has been reported in immunocompetent children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/15\">",
"     15",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Uvulitis due to viral infections has not been reported, but it is not clear that this been systematically studied. Viral infections that involve the oropharynx, including coxsackie viruses (and other enteroviruses), herpes simplex virus, and varicella-zoster virus, may cause lesions on the uvula, but rarely as isolated phenomena. Whether the uvula is susceptible to involvement during adenovirus or Epstein-Barr virus-induced pharyngitis is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Noninfectious causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uvular inflammation or edema may follow or be a manifestation of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trauma during airway or other instrumentation (eg, intubation, orogastric tube placement, airway suctioning, upper endoscopy, adenoidectomy) (",
"      <a class=\"graphic graphic_picture graphicRef83871 \" href=\"UTD.htm?34/5/34900\">",
"       picture 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/16-18\">",
"       16-18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Inhalation/ingestion",
"      </span>",
"      of chemical irritants (including cannabis) (",
"      <a class=\"graphic graphic_picture graphicRef83870 \" href=\"UTD.htm?43/32/44544\">",
"       picture 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/19-21\">",
"       19-21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Inhalation of steam (and presumably other sources of heated air) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Vasculitis (eg, Kawasaki disease) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Allergic reactions [",
"      <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Angioedema of the uvula (Quincke's edema) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/25-28\">",
"       25-28",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Uvular edema may be a manifestation of hereditary angioneurotic edema, with or without C1 inhibitor deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=see_link\">",
"       \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=see_link\">",
"       \"Hereditary angioedema: Pathogenesis and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Angioedema of the uvula also has been reported in association with the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"       lisinopril",
"      </a>",
"      , an angiotensin-converting enzyme inhibitor (a class of drugs known to be associated with angioedema) and following ingestion of herbal preparations from the squirting cucumber (",
"      <em>",
"       Ecbalium elaterium",
"      </em>",
"      ), a vine native to the Mediterranean region [",
"      <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=see_link&amp;anchor=H11#H11\">",
"       \"An overview of angioedema: Pathogenesis and causes\", section on 'ACE inhibitors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uvulitis is an acute cellulitis with typical marked edema and erythema (",
"    <a class=\"graphic graphic_picture graphicRef67939 \" href=\"UTD.htm?31/19/32049\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/1\">",
"     1",
"    </a>",
"    ]. Bacterial uvulitis likely arises from direct invasion by microbes on the epithelial surface following oropharyngeal colonization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    overgrowth; bacteremia may follow, particularly with",
"    <em>",
"     H. influenzae",
"    </em>",
"    type b (Hib) and anaerobes (",
"    <em>",
"     F. nucleatum, P. intermedia)",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/7,9\">",
"     7,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noninfectious uvulitis may result from direct mechanical or chemical injury with epithelial disruption",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tissue necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/16-22\">",
"     16-22",
"    </a>",
"    ]. Allergen exposure also can lead to uvular edema [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Noninfectious causes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H684614071\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with uvulitis may present with fever, sore throat, difficulty or pain with swallowing, drooling,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory distress [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. The clinical features vary depending upon the etiology. Respiratory distress is uncommon in infectious uvulitis unless there is associated epiglottitis. Isolated uvulitis may generate a sensation of localized pain or soreness in the back of the throat that is worse with swallowing.",
"   </p>",
"   <p>",
"    Group A streptococcus (GAS) uvulitis typically occurs with GAS pharyngitis. The predominant clinical features of GAS uvulitis are low-grade fever and sore throat. The enlarged, edematous uvula can cause a choking or gagging sensation or pain as it touches the base of the tongue or posterior wall of the pharynx [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/4\">",
"     4",
"    </a>",
"    ]. Drooling and oropharyngeal dysphagia are common, and cough and spitting can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <em>",
"     H. influenzae",
"    </em>",
"    type b (Hib) uvulitis may be associated with epiglottitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bacteremia, particularly in young children who did not receive Hib vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The predominant clinical features of Hib epiglottitis are sudden onset of high fever, difficulty swallowing, drooling, and respiratory distress (",
"    <a class=\"graphic graphic_table graphicRef80169 \" href=\"UTD.htm?25/10/25773\">",
"     table 2",
"    </a>",
"    ). However, there have been case reports of uvulitis with concomitant epiglottitis in which the epiglottitis was not suspected clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Significant upper airway obstruction from uvular edema is uncommon in the absence of associated epiglottitis. When airway obstruction does occur, the etiology of uvular swelling is usually noninfectious (eg, angioedema, chemical irritants) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/17,21,28,30\">",
"     17,21,28,30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Noninfectious causes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H684613935\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination efforts should be individualized according to the severity of illness. In young children with fever, drooling, and signs of respiratory distress or anxiousness (ie, possible epiglottitis), the oropharyngeal examination should be undertaken with great care (",
"    <a class=\"graphic graphic_table graphicRef80169 \" href=\"UTD.htm?25/10/25773\">",
"     table 2",
"    </a>",
"    ). In such children, the use of tongue blades generally should be avoided. Attempts to examine the oropharynx of children with epiglottitis may precipitate complete airway obstruction and cardiopulmonary arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/31\">",
"     31",
"    </a>",
"    ]. If the clinical suspicion of epiglottitis is high (eg, anxious, drooling, toxic-appearing child, with signs of respiratory distress), epiglottitis management protocols may need to be rapidly initiated. Direct laryngoscopy under anesthesia and controlled conditions by an experienced otolaryngologist or anesthesiologist is optimal. Young children with less extreme symptoms may be gently approached in the upright position (preferably sitting on the lap of a parent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link&amp;anchor=H31#H31\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\", section on 'Visualization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oropharyngeal examination may be difficult if the patient is unable to open his or her mouth wide enough for an adequate examination (as may occur with retropharyngeal or peritonsillar abscess or cellulitis). In such cases, computed tomography (CT) with contrast may be warranted. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Examination findings in patients with uvulitis may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A red, swollen uvula (",
"      <a class=\"graphic graphic_picture graphicRef67939 \" href=\"UTD.htm?31/19/32049\">",
"       picture 1",
"      </a>",
"      ), consistent with uvulitis. The uvula may be covered by purulent exudates.",
"     </li>",
"     <li>",
"      Pharyngeal edema, palatal petechiae, tonsillar enlargement and exudates if there is concomitant pharyngitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=see_link\">",
"       \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5738?source=see_link\">",
"       \"Evaluation of acute pharyngitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examination findings more consistent with other conditions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Midline or unilateral swelling of the posterior pharyngeal wall, suggestive of retropharyngeal abscess or cellulitis; additional findings may include stridor, tachypnea, and unwillingness to extend the neck. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=see_link\">",
"       \"Retropharyngeal infections in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=see_link\">",
"       \"Deep neck space infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tonsillar swelling with deviation of the uvula",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an obvious abscess at the superior pole of the tonsil, suggestive of peritonsillar abscess (",
"      <a class=\"graphic graphic_picture graphicRef69943 \" href=\"UTD.htm?29/54/30575\">",
"       picture 4",
"      </a>",
"      ). Uvular swelling and erythema are not typically present in patients with peritonsillar abscess; however, one case of uvulitis in association with peritonsillar abscess has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/61/31705?source=see_link\">",
"       \"Peritonsillar cellulitis and abscess\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vesicular lesions on the pharyngeal and oral mucosa, suggestive of herpes simplex virus or Coxsackie virus gingivostomatitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30216?source=see_link&amp;anchor=H21#H21\">",
"       \"Soft tissue lesions of the oral cavity in children\", section on 'Infections'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/27/31160?source=see_link&amp;anchor=H7#H7\">",
"       \"Herpetic gingivostomatitis in young children\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189237282\">",
"    <span class=\"h2\">",
"     Clinical diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of uvulitis is made clinically in patients with characteristic findings: fever and red, swollen uvula, with or without purulent exudates (",
"    <a class=\"graphic graphic_picture graphicRef67939 \" href=\"UTD.htm?31/19/32049\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging may be necessary to exclude subclinical epiglottitis or other conditions in the differential diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/1,11-13\">",
"     1,11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that lateral neck radiographs be obtained to evaluate the epiglottis in patients with uvulitis",
"    <strong>",
"     without",
"    </strong>",
"    pharyngitis or clinical features that suggest a noninfectious etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/1\">",
"     1",
"    </a>",
"    ]. Epiglottitis and subclinical epiglottitis have been described in patients with uvulitis due to",
"    <em>",
"     H. influenzae",
"    </em>",
"    type b (Hib) and",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiographic evaluation of the epiglottis usually is not necessary in patients with uvulitis and pharyngitis or noninfectious etiologies. Uvulitis and pharyngitis usually are caused by group A streptococcus (GAS); associated epiglottitis has not been reported.",
"   </p>",
"   <p>",
"    We suggest CT with contrast of the neck in patients who are unable to open their mouths wide enough for adequate examination. It is important to exclude peritonsillar abscess and retropharyngeal",
"    <span class=\"nowrap\">",
"     abscess/cellulitis",
"    </span>",
"    (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51505 \" href=\"UTD.htm?11/46/12015\">",
"     image 2",
"    </a>",
"    ) in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=see_link\">",
"     \"Retropharyngeal infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/61/31705?source=see_link\">",
"     \"Peritonsillar cellulitis and abscess\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=see_link\">",
"     \"Deep neck space infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing is necessary to determine the causative organism and antimicrobial susceptibility pattern in infectious uvulitis. Laboratory testing also may be necessary in cases of uvulitis associated with uvular angioedema.",
"   </p>",
"   <p>",
"    The microbiologic diagnosis is made by culture of specimens swabbed from the uvula or throat, or blood cultures. The timing and type of microbiologic specimens depends upon the clinical scenario.",
"   </p>",
"   <p>",
"    <strong>",
"     Uvulitis and suspected epiglottitis",
"    </strong>",
"    &ndash; In patients with uvulitis and suspected epiglottitis, blood cultures and surface cultures of the uvula and epiglottis should be obtained after the airway is secure (",
"    <a class=\"graphic graphic_table graphicRef80169 \" href=\"UTD.htm?25/10/25773\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If Hib is suspected (ie, in children younger than five years who are incompletely immunized against Hib), upper airway specimens should be plated on chocolate agar in addition to the blood agar that is used routinely for culture of GAS [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41608?source=see_link&amp;anchor=H2#H2\">",
"     \"Microbiology, epidemiology and treatment of Haemophilus influenzae\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Uvulitis and pharyngitis",
"    </strong>",
"    &ndash; In patients with uvulitis and pharyngitis, GAS is usually the causative organism and invasive disease is unlikely. In addition to surface cultures of the uvula, rapid antigen detection tests for GAS",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    throat culture should be obtained to confirm the etiology. Blood culture is seldom helpful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=see_link&amp;anchor=H17#H17\">",
"     \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\", section on 'Identifying GAS pharyngitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5738?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation of acute pharyngitis in adults\", section on 'Diagnostic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Isolated uvulitis &ndash;",
"    </strong>",
"    In patients with isolated uvulitis (ie, uvulitis without pharyngitis), surface cultures of the uvula and throat and blood cultures should be obtained when an infectious etiology is suspected. In patients with bacterial uvulitis, bacteremia may occur with or without associated epiglottitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/6,7,9\">",
"     6,7,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children younger than five years who have not received the Hib vaccine or are inadequately vaccinated against Hib, Hib should be considered a potential etiology. In such children, upper airway specimens should be plated on both chocolate agar and blood agar (for Hib and GAS, respectively). [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41608?source=see_link&amp;anchor=H2#H2\">",
"     \"Microbiology, epidemiology and treatment of Haemophilus influenzae\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Uvular edema",
"    </strong>",
"    &ndash; In patients with uvular edema, complete blood count with differential may be helpful. Eosinophilia in the peripheral blood suggests an allergic etiology, although the absence of eosinophilia does not exclude an allergic reaction. Evaluation of patients with uvular angioedema is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15641?source=see_link&amp;anchor=H9#H9\">",
"     \"An overview of angioedema: Clinical features, diagnosis, and management\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of uvulitis includes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Epiglottitis",
"     </li>",
"     <li>",
"      Retropharyngeal abscesses or cellulitis",
"     </li>",
"     <li>",
"      Peritonsillar abscess",
"     </li>",
"     <li>",
"      Angioedema",
"     </li>",
"     <li>",
"      Viral enanthem",
"     </li>",
"     <li>",
"      Severe pharyngitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These conditions usually can be differentiated from uvulitis by history and physical examination.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epiglottitis &ndash; In young children, epiglottitis typically presents with fever, drooling, anxiety, and rapid progression of upper airway obstruction (particularly when caused by",
"      <em>",
"       Haemophilus influenzae",
"      </em>",
"      type b). Although uvulitis may be associated with upper airway obstruction when due to noninfectious causes, upper airway obstruction is not a typical manifestation of infectious uvulitis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link\">",
"       \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Retropharyngeal abscess or cellulitis &ndash; Clinical features that may help to differentiate retropharyngeal abscess or cellulitis from uvulitis include intense pain with swallowing, drooling, stridor, tachypnea, unwillingness to move the neck (particularly with extension), and possibly inability to open the mouth wide enough for an adequate examination [",
"      <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/32\">",
"       32",
"      </a>",
"      ]. When oropharyngeal examination is possible, midline or unilateral swelling of the posterior pharyngeal wall may be detected. The diagnosis of retropharyngeal abscess or cellulitis is confirmed with CT scan of the neck with contrast (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51505 \" href=\"UTD.htm?11/46/12015\">",
"       image 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Imaging'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=see_link\">",
"       \"Retropharyngeal infections in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=see_link\">",
"       \"Deep neck space infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Peritonsillar abscess &ndash; Clinical features that help to distinguish peritonsillar abscess from uvulitis include drooling, trismus (which may limit the examination), and a \"hot potato\" muffled voice. Examination findings of peritonsillar abscess may include tonsillar swelling with deviation of the uvula",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an obvious abscess at the superior pole of the tonsil (",
"      <a class=\"graphic graphic_picture graphicRef69943 \" href=\"UTD.htm?29/54/30575\">",
"       picture 4",
"      </a>",
"      ). Uvular swelling and erythema are not typically present in patients with peritonsillar abscess; however, one case of uvulitis in association with peritonsillar abscess has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/61/31705?source=see_link\">",
"       \"Peritonsillar cellulitis and abscess\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Angioedema &ndash; The angioedematous uvula usually is not erythematous, but whitish and grape-like in appearance [",
"      <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/27\">",
"       27",
"      </a>",
"      ]. Eosinophilia in the peripheral blood suggests an allergic reaction as the etiology, although absence of eosinophilia does not exclude an allergic reaction. A low complement C4 level is suggestive of hereditary angioedema [",
"      <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=see_link\">",
"       \"An overview of angioedema: Pathogenesis and causes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Viral enanthem &ndash; Simple visualization of the oropharynx generally is sufficient to exclude the diagnoses of herpetic gingivostomatitis or other viral enanthem, such as Coxsackie virus (",
"      <a class=\"graphic graphic_picture graphicRef58566 graphicRef71314 \" href=\"UTD.htm?12/41/12949\">",
"       picture 5A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Severe pharyngitis &ndash; Severe bacterial or viral pharyngitis is usually characterized by erythema and edema of the posterior pharynx. Palatal petechiae and tonsillar enlargement and exudate may be present. Uvulitis may occur in conjunction with GAS pharyngitis; whether it occurs with other types of infectious pharyngitis (eg, adenovirus, Epstein-Barr virus) has not been well studied. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=see_link&amp;anchor=H2#H2\">",
"       \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\", section on 'Etiology and clinical clues'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H5\">",
"       'Infectious causes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of uvulitis depends upon the etiology, severity, and associated complaints. Patients with upper airway obstruction (secondary to epiglottitis or uvular edema) require admission to the hospital for airway management [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Infectious uvulitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of infectious uvulitis has not been studied systematically. The initial antimicrobial choice based upon coverage of the most likely organisms to cause infection and is guided by the clinical features (eg, associated epiglottitis or pharyngitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/1\">",
"     1",
"    </a>",
"    ]. Definitive therapy is guided by culture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H610444081\">",
"    <span class=\"h3\">",
"     Uvulitis with epiglottitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epiglottitis requires emergent management whether or not it is associated with uvulitis (",
"    <a class=\"graphic graphic_table graphicRef80169 \" href=\"UTD.htm?25/10/25773\">",
"     table 2",
"    </a>",
"    ). If epiglottitis is suspected or confirmed in a patient with uvulitis, the airway must be secured and appropriate antimicrobial therapy administered as soon as possible. The treatment of epiglottitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/16/12553?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268475023\">",
"    <span class=\"h3\">",
"     Uvulitis with pharyngitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with uvulitis and pharyngitis, group A streptococcus (GAS) is the most common cause. The natural history of GAS uvulitis is the same as that of GAS pharyngitis. The primary role of treatment is to hasten clinical improvement and reduce the risk of sequelae. GAS uvulitis and pharyngitis is treated in the same way as GAS pharyngitis without uvulitis. Most patients with uvulitis and pharyngitis can be treated as outpatients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=see_link\">",
"     \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with GAS uvulitis and pharyngitis, we suggest treatment with a penicillin antibiotic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/35\">",
"     35",
"    </a>",
"    ]. Macrolide-based regimens can be used for penicillin-allergic patients. Appropriate regimens are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef64596 \" href=\"UTD.htm?21/29/21981\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Symptomatic treatment of throat pain in patients with pharyngitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27224?source=see_link\">",
"     \"Symptomatic relief of sore throat in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38455?source=see_link\">",
"     \"Symptomatic treatment of acute pharyngitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Isolated uvulitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uvulitis without epiglottitis or pharyngitis may be caused by a number of pathogens, including",
"    <em>",
"     H. influenzae",
"    </em>",
"    type b (Hib),",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    , anaerobes",
"    <em>",
"    </em>",
"    (",
"    <em>",
"     eg, F. nucleatum, P. intermedia",
"    </em>",
"    ), and",
"    <em>",
"     Candida",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/7,9-13\">",
"     7,9-13",
"    </a>",
"    ]. The initial antibiotic choice is guided by clinical features (eg, age, immunization status). Antimicrobial therapy should be amended as indicated when culture and susceptibility results are available. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Infectious causes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H610444935\">",
"    <span class=\"h4\">",
"     Parenteral versus oral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions regarding initial parenteral versus oral antimicrobial therapy in patients with suspected bacterial uvulitis must be made on a case-by-case basis, depending upon the severity of the symptoms and ability to return for follow-up.",
"   </p>",
"   <p>",
"    We suggest that children &lt;5 years of age who are inadequately immunized against Hib and",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    receive initial parenteral therapy because of the possibility of bacteremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H610444747\">",
"    <span class=\"h4\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that empiric antimicrobial therapy for infectious uvulitis include coverage for both Hib and",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    . Local antimicrobial susceptibility patterns must be taken into consideration when choosing empiric therapy. Coverage for anaerobic pathogens also may be warranted in clinical scenarios that include associated signs of dental infection, findings concerning for necrotizing tonsillar or peritonsillar abscess, or gangrenous appearance of the uvula. Empiric antifungal therapy may be warranted for patients with clinical features of oral thrush (ie, white plaques (",
"    <a class=\"graphic graphic_picture graphicRef61040 graphicRef82214 \" href=\"UTD.htm?10/60/11207\">",
"     picture 6A-B",
"    </a>",
"    )).",
"   </p>",
"   <p>",
"    Empiric parenteral regimens that include coverage for Hib and",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      50 to 100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day intravenously (IV) in one or two doses (maximum daily dose 2 g),",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       Cefotaxime",
"      </a>",
"      150 to 200",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in three or four divided doses (maximum daily dose 10 g)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Empiric oral regimens that may be used if penicillin nonsusceptible",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    is",
"    <strong>",
"     not",
"    </strong>",
"    a concern include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       Amoxicillin-clavulanate",
"      </a>",
"      45",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      component orally divided in two doses (maximum daily dose 1750 mg),",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"       Cefuroxime",
"      </a>",
"      axetil 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day orally divided in two doses (maximum daily dose 500 mg),",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/21/5461?source=see_link\">",
"       Cefdinir",
"      </a>",
"      14",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day orally divided in two doses (maximum daily dose 600 mg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fluoroquinolones (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice daily for children six months to five years; 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once daily for patients &ge;5 years [maximum daily dose 500 mg]) are an option for oral therapy if penicillin nonsusceptible",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    is a concern. Fluoroquinolones are also an option for parenteral or oral therapy in patients with an allergy to penicillin and cephalosporins. For patients younger than 18 years of age, fluoroquinolones generally are reserved for cases in which there is no other safe and effective alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/36\">",
"     36",
"    </a>",
"    ]. Oral fluoroquinolones may be warranted when the only other options require parenteral administration.",
"   </p>",
"   <p>",
"    There is little evidence to guide the treatment of candidal uvulitis. In case reports, one patient with uvulitis apparently caused by",
"    <em>",
"     C. albicans",
"    </em>",
"    responded promptly to topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    , and another improved spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/15\">",
"     15",
"    </a>",
"    ]. Systemic antifungal therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    may be warranted in immunocompromised hosts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H610444761\">",
"    <span class=\"h4\">",
"     Duration of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total duration of therapy should be 7 to 10 days, provided the patient improves as expected [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients who are initially treated with parenteral therapy can be switched to oral therapy when they are afebrile and clinically improved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Noninfectious uvulitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninfectious uvulitis generally resolves spontaneously without sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/5,16-18,20,23,24\">",
"     5,16-18,20,23,24",
"    </a>",
"    ]. Treatment is symptomatic. In case reports, analgesics, local anesthetic lozenges, topical anesthetics (eg, viscous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ), and ice chips have been associated with symptomatic relief [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/16,18,20,24\">",
"     16,18,20,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Airway obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In case reports, topical epinephrine and systemic glucocorticoids and antihistamines have been beneficial in patients of severe uvular swelling associated with airway obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/5,17,18,20,21,25,28,37\">",
"     5,17,18,20,21,25,28,37",
"    </a>",
"    ]. Uvulectomy also has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/34,38\">",
"     34,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most case series, infectious and noninfectious uvulitis appear to resolve without sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/5,16-18,20,23,24\">",
"     5,16-18,20,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H610444342\">",
"    <span class=\"h2\">",
"     Vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In countries that routinely administer",
"    <em>",
"     H. influenzae",
"    </em>",
"    type b (Hib) vaccines to infants and young children, Hib uvulitis has essentially been eliminated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42489?source=see_link&amp;anchor=H7#H7\">",
"     \"Prevention of Haemophilus influenzae infection\", section on 'Efficacy/effectiveness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several candidate vaccines for group A streptococcus (GAS) are in development, but there is no currently licensed vaccine for GAS [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10649/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment and prevention of streptococcal tonsillopharyngitis\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H610444349\">",
"    <span class=\"h2\">",
"     Chemoprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of nosocomial spread of Hib infection and chemoprophylaxis for close contacts of patients with invasive Hib disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42489?source=see_link&amp;anchor=H15#H15\">",
"     \"Prevention of Haemophilus influenzae infection\", section on 'Antibiotic prophylaxis of close contacts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uvulitis has infectious and noninfectious causes (",
"      <a class=\"graphic graphic_table graphicRef82234 \" href=\"UTD.htm?22/39/23163\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Group A streptococcus (GAS) is the most common bacterial cause of uvulitis. GAS uvulitis typically occurs with GAS pharyngitis. The predominant clinical features are low-grade fever and sore throat, but the enlarged uvula may cause a choking or gagging sensation and difficulty swallowing. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <em>",
"       Haemophilus influenzae",
"      </em>",
"      type b (Hib) uvulitis may be associated with epiglottitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bacteremia. The predominant clinical features of Hib epiglottitis are sudden onset of high fever, difficulty swallowing, and respiratory distress (",
"      <a class=\"graphic graphic_table graphicRef80169 \" href=\"UTD.htm?25/10/25773\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of uvulitis is made clinically in patients with characteristic findings: fever and red, swollen uvula, with or without purulent exudates (",
"      <a class=\"graphic graphic_picture graphicRef67939 \" href=\"UTD.htm?31/19/32049\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lateral neck radiographs may be warranted to exclude subclinical epiglottitis in patients with uvulitis without pharyngitis. Computed tomography with contrast of the neck may be necessary in patients who are unable to open their mouths widely for adequate examination. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The microbiologic diagnosis is made by culture of specimens swabbed from the uvula or throat, or blood cultures. The timing and type of microbiologic specimens depends upon the clinical scenario. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Laboratory studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of uvulitis includes epiglottitis (without uvulitis), retropharyngeal or peritonsillar",
"      <span class=\"nowrap\">",
"       abscess/cellulitis,",
"      </span>",
"      angioedema, viral enanthem, and severe pharyngitis (without uvulitis). These conditions can usually be differentiated from uvulitis by history and physical examination; imaging studies may be necessary if adequate examination of the oropharynx cannot be performed. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of uvulitis depends upon the severity and associated complaints.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Epiglottitis requires emergent management whether or not it is associated with uvulitis. The airway must be secured and appropriate antimicrobial therapy administered as soon as possible (",
"      <a class=\"graphic graphic_table graphicRef80169 \" href=\"UTD.htm?25/10/25773\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/16/12553?source=see_link\">",
"       \"Epiglottitis (supraglottitis): Treatment and prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with uvulitis and pharyngitis, which is usually caused by GAS, we suggest treatment with a penicillin antibiotic (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/46/23269?source=see_link\">",
"       penicillin V",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      are appropriate first-line agents (",
"      <a class=\"graphic graphic_table graphicRef64596 \" href=\"UTD.htm?21/29/21981\">",
"       table 3",
"      </a>",
"      ). A macrolide can be used for penicillin-allergic patients. (See",
"      <a class=\"local\" href=\"#H268475023\">",
"       'Uvulitis with pharyngitis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=see_link\">",
"       \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with isolated uvulitis, we suggest that empiric therapy include coverage for",
"      <em>",
"       Streptococcus pneumoniae",
"      </em>",
"      and Hib (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The regimen of choice depends upon local antimicrobial susceptibility patterns for",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      . Antimicrobial therapy should be amended as indicated when culture and susceptibility results are available. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Isolated uvulitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H610444747\">",
"       'Choice of agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that children &lt;5 years of age with isolated uvulitis who are inadequately immunized against Hib and",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      receive initial parenteral therapy because of the possibility of bacteremia. (See",
"      <a class=\"local\" href=\"#H610444935\">",
"       'Parenteral versus oral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Wald ER. Uvulitis. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison, GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.176.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/2\">",
"      Olofsson K, Mattsson C, Hammarstr&ouml;m ML, Hellstr&ouml;m S. Structure of the human uvula. Acta Otolaryngol 1999; 119:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/3\">",
"      Olofsson K, Hellstr&ouml;m S, Hammarstr&ouml;m ML. Human uvula: characterization of resident leukocytes and local cytokine production. Ann Otol Rhinol Laryngol 2000; 109:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/4\">",
"      Kotloff KL, Wald ER. Uvulitis in children. Pediatr Infect Dis 1983; 2:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/5\">",
"      McNamara RM. Clinical characteristics of acute uvulitis. Am J Emerg Med 1994; 12:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/6\">",
"      Li KI, Kiernan S, Wald ER, Reilly JS. Isolated uvulitis due to Haemophilus influenzae type b. Pediatrics 1984; 74:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/7\">",
"      Wynder SG, Lampe RM, Shoemaker ME. Uvulitis and Hemophilus influenzae b bacteremia. Pediatr Emerg Care 1986; 2:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/8\">",
"      Aquino V, Terndrup TE. Uvulitis in three children: etiology and respiratory distress. Pediatr Emerg Care 1992; 8:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/9\">",
"      Brook I. Uvulitis caused by anaerobic bacteria. Pediatr Emerg Care 1997; 13:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/10\">",
"      Westerman EL, Hutton JP. Acute uvulitis associated with epiglottitis. Arch Otolaryngol Head Neck Surg 1986; 112:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/11\">",
"      Rapkin RH. Simultaneous uvulitis and epiglottitis. JAMA 1980; 243:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/12\">",
"      McNamara R, Koobatian T. Simultaneous uvulitis and epiglottitis in adults. Am J Emerg Med 1997; 15:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/13\">",
"      Jerrard DA, Olshaker J. Simultaneous uvulitis and epiglottitis without fever or leukocytosis. Am J Emerg Med 1996; 14:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/14\">",
"      Costa A, Nery J, Oliveira M, et al. Oral lesions in leprosy. Indian J Dermatol Venereol Leprol 2003; 69:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/15\">",
"      Krober MS, Weir MR. Acute uvulitis apparently caused by Candida albicans. Pediatr Infect Dis J 1991; 10:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/16\">",
"      Peghini PL, Salcedo JA, Al-Kawas FH. Traumatic uvulitis: a rare complication of upper GI endoscopy. Gastrointest Endosc 2001; 53:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/17\">",
"      Tabboush ZS. Airway obstruction from uvular edema after traumatic adenoidectomy. Anesth Analg 2000; 91:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/18\">",
"      Gilmore T, Mirin M. Traumatic uvulitis from a suction catheter. J Emerg Med 2012; 43:e479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/19\">",
"      Guarisco JL, Cheney ML, LeJeune FE Jr, Reed HT. Isolated uvulitis secondary to marijuana use. Laryngoscope 1988; 98:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/20\">",
"      Boyce SH, Quigley MA. Uvulitis and partial upper airway obstruction following cannabis inhalation. Emerg Med (Fremantle) 2002; 14:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/21\">",
"      Mallat A, Roberson J, Brock-Utne JG. Preoperative marijuana inhalation--an airway concern. Can J Anaesth 1996; 43:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/22\">",
"      Duggal MS, Main DM. Acute uvulitis: a sauna hazard. Br Dent J 1988; 165:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/23\">",
"      Kazi A, Gauthier M, Lebel MH, et al. Uvulitis and supraglottitis: early manifestations of Kawasaki disease. J Pediatr 1992; 120:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/24\">",
"      Butterton JR, Clawson-Simons J. Hymenoptera uvulitis. N Engl J Med 1987; 317:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/25\">",
"      Deutsch ES, Zalzal GH. Quincke's edema, revisited. Arch Otolaryngol Head Neck Surg 1991; 117:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/26\">",
"      Bork K, G&uuml;l D, Hardt J, Dewald G. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am J Med 2007; 120:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/27\">",
"      Evans TC, Roberge RJ. Quincke's disease of the uvula. Am J Emerg Med 1987; 5:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/28\">",
"      Claes P, Devue K, Beckers R, et al. Sudden drooling and supine gagging: an important emergency? Eur J Emerg Med 2005; 12:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/29\">",
"      Kuo DC, Barish RA. Isolated uvular angioedema associated with ACE inhibitor use. J Emerg Med 1995; 13:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/30\">",
"      Satar S, Gokel Y, Toprak N, Sebe A. Life-threatening uvular angioedema caused by Ecbalium elaterium. Eur J Emerg Med 2001; 8:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/31\">",
"      Blanc VF, Weber ML, Leduc C, et al. Acute epiglottitis in children: management of 27 consecutive cases with nasotracheal intubation, with special emphasis on anaesthetic considerations. Can Anaesth Soc J 1977; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/32\">",
"      Lee SS, Schwartz RH, Bahadori RS. Retropharyngeal abscess: epiglottitis of the new millennium. J Pediatr 2001; 138:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/33\">",
"      Cohen M, Chhetri DK, Head C. Isolated uvulitis. Ear Nose Throat J 2007; 86:462, 464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/34\">",
"      Goldberg R, Lawton R, Newton E, Line WS Jr. Evaluation and management of acute uvular edema. Ann Emerg Med 1993; 22:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/35\">",
"      Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis 2012; 55:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/36\">",
"      Bradley JS, Jackson MA, Committee on Infectious Diseases, American Academy of Pediatrics. The use of systemic and topical fluoroquinolones. Pediatrics 2011; 128:e1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/37\">",
"      Roberge RJ, Sullivan T. Topical epinephrine therapy of acute uvulitis. Am J Emerg Med 1997; 15:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/38\">",
"      Hawke M, Kwok P. Acute inflammatory edema of the uvula (uvulitis) as a cause of respiratory distress: a case report. J Otolaryngol 1987; 16:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10649/abstract/39\">",
"      Dale JB. Current status of group A streptococcal vaccine development. Adv Exp Med Biol 2008; 609:53.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6029 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-E64CDCC3B7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_25_10649=[""].join("\n");
var outline_f10_25_10649=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Infectious causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Noninfectious causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H684614071\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H684613935\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H189237282\">",
"      Clinical diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Infectious uvulitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H610444081\">",
"      - Uvulitis with epiglottitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H268475023\">",
"      - Uvulitis with pharyngitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Isolated uvulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H610444935\">",
"      Parenteral versus oral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H610444747\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H610444761\">",
"      Duration of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Noninfectious uvulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H610444342\">",
"      Vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H610444349\">",
"      Chemoprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6029\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6029|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/26/22958\" title=\"diagnostic image 1\">",
"      Epiglottitis x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/46/12015\" title=\"diagnostic image 2\">",
"      Retropharyngeal abscess CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6029|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/19/32049\" title=\"picture 1\">",
"      Uvulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/5/34900\" title=\"picture 2\">",
"      Uvular edema tonsillectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/32/44544\" title=\"picture 3\">",
"      Uvular edema caustic ingestion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/54/30575\" title=\"picture 4\">",
"      Peritonsillar abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/2/13344\" title=\"picture 5A\">",
"      Hand-foot-and-mouth disease - buccal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/27/20912\" title=\"picture 5B\">",
"      Hand-foot-and-mouth disease - tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/30/28128\" title=\"picture 6A\">",
"      Oral candidiasis - palate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/42/12963\" title=\"picture 6B\">",
"      Oral candidiasis - tongue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6029|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/39/23163\" title=\"table 1\">",
"      Causes uvulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/10/25773\" title=\"table 2\">",
"      Epiglottitis in children &ndash; Rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/29/21981\" title=\"table 3\">",
"      Treatment streptococcal pharyngitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15641?source=related_link\">",
"      An overview of angioedema: Clinical features, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=related_link\">",
"      An overview of angioedema: Pathogenesis and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=related_link\">",
"      Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=related_link\">",
"      Deep neck space infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=related_link\">",
"      Epiglottitis (supraglottitis): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/16/12553?source=related_link\">",
"      Epiglottitis (supraglottitis): Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5738?source=related_link\">",
"      Evaluation of acute pharyngitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39415?source=related_link\">",
"      Evaluation of sore throat in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=related_link\">",
"      Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=related_link\">",
"      Hereditary angioedema: Pathogenesis and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/27/31160?source=related_link\">",
"      Herpetic gingivostomatitis in young children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41608?source=related_link\">",
"      Microbiology, epidemiology and treatment of Haemophilus influenzae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/61/31705?source=related_link\">",
"      Peritonsillar cellulitis and abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42489?source=related_link\">",
"      Prevention of Haemophilus influenzae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=related_link\">",
"      Retropharyngeal infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30216?source=related_link\">",
"      Soft tissue lesions of the oral cavity in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27224?source=related_link\">",
"      Symptomatic relief of sore throat in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38455?source=related_link\">",
"      Symptomatic treatment of acute pharyngitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=related_link\">",
"      Treatment and prevention of streptococcal tonsillopharyngitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_25_10650="Overview of the management of gender nonconformity in children and adolescents";
var content_f10_25_10650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the management of gender nonconformity in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/25/10650/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/25/10650/contributors\">",
"     Johanna Olson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/25/10650/contributors\">",
"     Michelle Forcier, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/25/10650/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/25/10650/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/25/10650/contributors\">",
"     David Brent, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/25/10650/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/25/10650/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/25/10650/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/25/10650/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H25477371\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children generally are assigned a gender at birth based upon genital anatomy or chromosomes. For most children, gender assignment correlates with gender identity, which is the innate sense of maleness or femaleness. However, some children have a gender identity that does not correlate with assigned gender. These children are called gender nonconforming, gender variant, or sometimes transgender (",
"    <a class=\"graphic graphic_table graphicRef86993 \" href=\"UTD.htm?10/1/10269\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12378?source=see_link&amp;anchor=H182326064#H182326064\">",
"     \"Overview of gender development and clinical presentation of gender nonconformity in children and adolescents\", section on 'Terminology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The trajectory of gender nonconformity in childhood is unpredictable; some children with gender nonconformity will grow up to be transgender adults and some will grow up to be cis-gendered adults (ie, adults in whom gender identity matches genital anatomy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12378?source=see_link&amp;anchor=H584043130#H584043130\">",
"     \"Overview of gender development and clinical presentation of gender nonconformity in children and adolescents\", section on 'Trajectory'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will provide an overview of the management of gender nonconformity in children and adolescents. Gender development and the clinical presentation of gender nonconformity in children and adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12378?source=see_link&amp;anchor=H233847#H233847\">",
"     \"Overview of gender development and clinical presentation of gender nonconformity in children and adolescents\", section on 'Referral'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H231831\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little evidence to guide the management of gender nonconformity in children and adolescents and opinions about the best treatment vary [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Most experience comes from case series of adults who underwent sex reassignment surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/3\">",
"     3",
"    </a>",
"    ]. However, as the number of multidisciplinary centers providing treatment for gender-nonconforming youth increases, information about outcomes in this population is increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/4-11\">",
"     4-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8602?source=see_link\">",
"     \"Treatment of transsexualism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians have differing views on whether gender nonconformity should be regarded as a normal variation of gender expression, a medical condition, or a psychiatric disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/12\">",
"     12",
"    </a>",
"    ]. In the absence of a clear understanding of the etiology of gender nonconformity, these views influence the management approach. Approaches to treating gender-nonconforming children and adolescents have been outlined by the",
"    <a class=\"external\" href=\"file://www.endo-society.org/guidelines/final/upload/Endocrine-Treatment-of-Transsexual-Persons.pdf\">",
"     Endocrine Society",
"    </a>",
"    , the",
"    <a class=\"external\" href=\"file://www.aacap.org/galleries/PracticeParameters/glbt_practice_parameter_june_2012.pdf\">",
"     American Academy of Child and Adolescent Psychiatry",
"    </a>",
"    , and the",
"    <a class=\"external\" href=\"file://www.wpath.org/\">",
"     World Professional Association for Transgender Health",
"    </a>",
"    (WPATH) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/2,13,14\">",
"     2,13,14",
"    </a>",
"    ]. Our approach is generally consistent with the recommendations in these guidelines.",
"   </p>",
"   <p>",
"    The information provided in this topic review is intended to allow primary care providers to educate and support patients and families of gender-nonconforming youth and to coordinate care, provide referrals, provide additional psychosocial support from the medical home, and monitor patients receiving care from specialists (eg, monitoring lab work, drug side effects, drug-drug interactions, etc).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H231838\">",
"    <span class=\"h1\">",
"     GUIDING PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several principles guide the treatment of gender-nonconforming youth; these include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/1,8,9,14-17\">",
"     1,8,9,14-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The safety and well-being of the youth and his or her family members is foremost; treatment decisions must consider the potential for decreased sense of self-worth, depression, self-harm, suicidality, verbal victimization, physical victimization, etc. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12378?source=see_link&amp;anchor=H492231856#H492231856\">",
"       \"Overview of gender development and clinical presentation of gender nonconformity in children and adolescents\", section on 'Associated concerns'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Care for gender-nonconforming youth is determined on a case-by-case basis. Given the spectrum and fluidity of gender identity, it is important for health care providers to understand the specific needs of individual patients. The degree and type of mental health and medical support and interventions may vary. Not all gender-nonconforming youth desire phenotypic transformation.",
"     </li>",
"     <li>",
"      Clinicians who are neither comfortable nor willing to become sufficiently knowledgeable to treat transgendered patients should refer them to more experienced colleagues.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25477604\">",
"    <span class=\"h1\">",
"     TYPES OF INTERVENTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83439611\">",
"    <span class=\"h2\">",
"     Mental health interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several mental health approaches to help gender-nonconforming children and adolescents explore their gender identity and find a gender role that is comfortable [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/2\">",
"     2",
"    </a>",
"    ]. Treatment options may be influenced by cultural differences, opinions of health professionals, insurance coverage, and availability of services.",
"   </p>",
"   <p>",
"    The specific approach for a given child or adolescent is individualized. The process may or may not involve recommendations for a change in gender expression or body modification; what helps to alleviate gender dysphoria in one person may be very different from what helps to alleviate it in another.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Affirming",
"      </strong>",
"      &ndash; Affirming approaches focus on gender",
"      <span class=\"nowrap\">",
"       identity/body",
"      </span>",
"      congruence and actively promote exploration of gender development and self-definition within a safe setting [",
"      <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/1,18\">",
"       1,18",
"      </a>",
"      ]. A fundamental concept of this approach is that gender nonconformity is not a mental illness. There is no need to pathologize the child or adolescent&rsquo;s behaviors or to assign a diagnosis. With the help of affirming psychotherapy, some individuals can integrate their cross-gender feelings into the gender they were assigned at birth; others may be able to alleviate their gender dysphoria through changes in gender role and expression [",
"      <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/2,19\">",
"       2,19",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The authors of this topic review support affirming approaches&mdash;from both mental health professionals and",
"      <span class=\"nowrap\">",
"       parents/caregivers&mdash;for",
"      </span>",
"      gender-nonconforming youth.",
"     </li>",
"     <li>",
"      <strong>",
"       Wait-and-see",
"      </strong>",
"      &ndash; Some caregivers take a wait-and-see approach: waiting to see how the child&rsquo;s gender identity changes as he or she gets older [",
"      <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/1\">",
"       1",
"      </a>",
"      ]. Caregivers who take the wait-and-see approach may allow cross-gender play and clothing within the home. Caregivers may also support participation in both masculine and feminine activities as the child explores their interests in other social settings.",
"     </li>",
"     <li>",
"      <strong>",
"       Redirection &ndash;",
"      </strong>",
"      Some mental health therapists encourage caregivers to use positive reinforcement to try to &ldquo;redirect&rdquo; children toward behavior that is more typical of their genotypic sex or less gender specific. The goal of redirection is that that the gender-nonconforming desires and expressions may disappear over time [",
"      <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/20\">",
"       20",
"      </a>",
"      ]. Negative reinforcement (eg, shaming the child for gender-nonconforming expression) has significant negative mental and social health consequences should be avoided at all costs.",
"     </li>",
"     <li>",
"      <strong>",
"       Reparative therapy",
"      </strong>",
"      &ndash; Families who have great difficulty accepting their gender-nonconforming child might seek the help of mental health professionals who practice reparative therapy, claiming to be able to &ldquo;cure&rdquo; a transgender identity. This approach was initially used in the 1970s [",
"      <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. Reparative therapy is considered",
"      <strong>",
"       unhelpful and potentially harmful",
"      </strong>",
"      by most professional organizations, including the American Academy of Child and Adolescent Psychiatry, the World Professional Association for Transgender Health, and the Society for Adolescent Health and Medicine [",
"      <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/2,14,23\">",
"       2,14,23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83439674\">",
"    <span class=\"h2\">",
"     Phenotypic interventions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65066665\">",
"    <span class=\"h3\">",
"     Social transition",
"    </span>",
"    &nbsp;&mdash;&nbsp;&ldquo;Social transition&rdquo; is a reversible intervention in which the youth lives partially or completely in the preferred gender role by adapting hairstyle, clothing, pronouns, and possibly assuming a new name. Patients and families may decide to have a &ldquo;trial run&rdquo; to allow the child to see how it feels and the parents and health care providers to see how the child responds. Patients and families decide in advance the extent of the transition (eg, clothing, pronouns, name), whether and to whom to disclose the transition, and how to handle common potential challenges (eg, bathrooms, locker rooms, sleepovers, etc).",
"   </p>",
"   <p>",
"    Decisions regarding social transition are made on a case-by-case basis after considering the potential risks (eg, safety concerns) and benefits (eg, alleviation of psychologic distress) in consultation with the patient, parents, and trained mental health professionals [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/1\">",
"     1",
"    </a>",
"    ]. Although not well-studied, in a cohort of 97 patients (&lt;21 years) referred to a gender management service in a tertiary care center in the United States, symptoms of depression and anxiety improved when youth began social and physical transition [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety of the child or adolescent and the likelihood of acceptance in the community are important considerations in making decisions about social transition. Providers can help youth and families make positive and successful social transition plans by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Helping them plan for disclosure to family, friends, and social contacts",
"     </li>",
"     <li>",
"      Educating staff and students within the school system",
"     </li>",
"     <li>",
"      Creating plans for safety, responses to bullying, and other social biases",
"     </li>",
"     <li>",
"      Providing medical documentation for name change, gender change, and other official documents; the",
"      <a class=\"external\" href=\"file://www.imatyfa.org/permanent_files/safefolder.html\">",
"       TransYouth Family Allies",
"      </a>",
"      Web site, among others, provides information about what to include in the medical documentation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These suggestions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12378?source=see_link&amp;anchor=H462800773#H462800773\">",
"     \"Overview of gender development and clinical presentation of gender nonconformity in children and adolescents\", section on 'Role of the medical provider'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It may be best to confine the social transition to the home if the school",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    community environments are considered to be hazardous for the youth&rsquo;s well being. However, it is important that parental assessment of the potential for danger is accurate. For parents who are unsure about the social transition or have difficulty accepting their gender-nonconforming child, safety concerns may be used to delay social transition. Families can contact a number of local or national social and advocacy agencies to assist in making a safety assessment or in facilitating a social transition in school. Such organizations work with schools, teachers, and students to assist in developing transition planning with bathroom and locker room accommodations, registration questions, and overall education about gender-related issues. The involvement of these agencies allows parents to focus on parenting their gender-nonconforming child rather than bringing about social change. (See",
"    <a class=\"local\" href=\"#H233854\">",
"     'Resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Parents of children and adolescents who are socially transitioned may request a &ldquo;safe letter&rdquo; from their child&rsquo;s medical or mental health provider to describe their child&rsquo;s situation in an effort to preempt discrimination or problems with authorities (eg, protective services, law enforcement, other institutional authorities) who are unfamiliar with gender nonconformity. Information to be included in a safe letter can be found on the",
"    <a class=\"external\" href=\"file://www.imatyfa.org/permanent_files/safefolder.html\">",
"     TransYouth Family Allies",
"    </a>",
"    Web site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65066672\">",
"    <span class=\"h3\">",
"     Hormonal interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormonal interventions (eg, suppression of endogenous puberty",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    initiation of cross-gender hormones to alter secondary sexual characteristics) may be warranted for adolescents with gender nonconformity and strong feelings of gender dysphoria after the onset of puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/4\">",
"     4",
"    </a>",
"    ]. These interventions are discussed in detail below. (See",
"    <a class=\"local\" href=\"#H113274158\">",
"     'Overview of hormonal interventions for adolescents'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191437845\">",
"    <span class=\"h3\">",
"     Surgical interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many youth and parents have questions about surgical interventions for gender confirmation. It is important to respond to these questions, acknowledge the possibility of surgical intervention in the future, and to make referrals as necessary when youth reach an age when surgery may be appropriate. However, for children and early adolescents, it is also important to redirect to the focus to social and medical interventions. Early identification and intervention affirming gender-nonconforming children may help to avoid invasive gender confirmation surgeries in the future. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8602?source=see_link&amp;anchor=H27#H27\">",
"     \"Treatment of transsexualism\", section on 'Surgical sex reassignment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25477379\">",
"    <span class=\"h1\">",
"     APPROACH IN PREPUBERTAL CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trajectory of gender nonconformity in prepubertal children is unpredictable [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/12,24,25\">",
"     12,24,25",
"    </a>",
"    ]. There is no way to determine with certainty which children with gender nonconformity will have gender dysphoria in adolescence or adulthood, and which will not. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12378?source=see_link&amp;anchor=H9259024#H9259024\">",
"     \"Overview of gender development and clinical presentation of gender nonconformity in children and adolescents\", section on 'Prepubertal children'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The uncertainty of the trajectory makes it difficult to know which approach is best for an individual child. Given the uncertainty, it seems reasonable for the primary care provider to offer education, support, and referrals as indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Educate parents about the possible gender and psychosexual trajectories",
"     </li>",
"     <li>",
"      Encourage a wide range of interests and activities",
"     </li>",
"     <li>",
"      Follow the child&rsquo;s lead with respect to gender expression, but set limits as necessary for safety",
"     </li>",
"     <li>",
"      Protect the child against negative reactions from others",
"     </li>",
"     <li>",
"      Address concomitant emotional, behavioral, or family problems that may (or may not) have an impact on the child&rsquo;s gender dysphoria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional suggestions for education and support are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12378?source=see_link&amp;anchor=H233840#H233840\">",
"     \"Overview of gender development and clinical presentation of gender nonconformity in children and adolescents\", section on 'Education and support'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complete social transition is controversial in prepubertal children. Evidence is insufficient to predict the long-term outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/2\">",
"     2",
"    </a>",
"    ]. Given that the majority of children with gender dysphoria do not continue to have gender dysphoria in adulthood, the Endocrine Society and the Center of Expertise on Gender Dysphoria (formerly the Amsterdam Gender Clinic) recommend against a complete social transition for prepubertal children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]. This is to prevent youth with gender dysphoria that does not persist from having to make a complex change back to genotypic sex [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/26\">",
"     26",
"    </a>",
"    ]. However, in the experience of the authors of this topic review, there are children who simply cannot function adequately in their familial, social, and educational domains without being allowed to express their authentic internal gender identity. To date, there has been no evidence proving, or even suggesting harm, resulting from a child who has socially transitioned in childhood and remitted to his or her birth gender at a later age. In some cases, it is possible that supporting a potentially temporary social transition may be helpful in improving the functioning of a gender dysphoric child. Mental and medical health professionals agree that the approach should be individualized for each child; that the parents&rsquo; role is to support what is best for the child; and that all children are more likely to have a healthy self-image, self-esteem, and general well-being when their authentic identity is recognized, supported, and loved. (See",
"    <a class=\"local\" href=\"#H65066665\">",
"     'Social transition'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12378?source=see_link&amp;anchor=H584043130#H584043130\">",
"     \"Overview of gender development and clinical presentation of gender nonconformity in children and adolescents\", section on 'Trajectory'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Referral to a mental health provider may be warranted for [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prepubertal children with evidence of gender dysphoria (eg, aversion to aspects of their body associated with sex; wish to live as opposite sex); coexisting anxiety, depression, or suicidality; or significant interpersonal conflicts with peers (eg, bullying) or parents. Bullying that occurs at school should also be addressed by school personnel.",
"     </li>",
"     <li>",
"      Peripubertal and post-pubertal youth who are not gender dysphoric but seeking additional psychosocial support and planning for transition (",
"      <a class=\"graphic graphic_table graphicRef87390 \" href=\"UTD.htm?13/29/13789\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Parents of gender-nonconforming children and adolescents who are uncomfortable with their child&rsquo;s behaviors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12378?source=see_link&amp;anchor=H233847#H233847\">",
"     \"Overview of gender development and clinical presentation of gender nonconformity in children and adolescents\", section on 'Referral'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25477701\">",
"    <span class=\"h1\">",
"     APPROACH IN PUBERTAL CHILDREN AND ADOLESCENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gender dysphoria that persists through the onset of puberty or is increased at the onset of puberty is unlikely to subside [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/4,6,28\">",
"     4,6,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most gender specialists suggest a supportive, affirming approach with an interdisciplinary team that includes medical and mental health specialists [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/1,2,13\">",
"     1,2,13",
"    </a>",
"    ]. Given the spectrum and fluidity of gender identity, the management needs and goals differ from adolescent to adolescent. Adolescents may change their transition goals and requests for treatment over time according to personal desire and circumstance.",
"   </p>",
"   <p>",
"    Some gender-nonconforming youth do not desire a phenotypic transition, and are content with their endogenous hormones. They may identify as transgender, or they may identify as something completely different. It is important for providers to try to understand the individual needs of each patient. Youth who identify as &ldquo;gender queer&rdquo; or androgynous (ie, somewhere between male and female) may or may not want to take cross-gender hormones, depending upon their level of gender dysphoria (ie, discomfort related to mismatch between gender identity and anatomic sex). Some may desire a low-level hormone dose to maintain a more androgynous effect.",
"   </p>",
"   <p>",
"    To allow time for the adolescent to develop the maturity necessary to make a thorough and informed decision about permanent physical changes, medical interventions generally progress from reversible (eg, social transition, pubertal suppression), to partially reversible interventions (eg, cross-gender hormones), to irreversible interventions (eg, surgical interventions). (See",
"    <a class=\"local\" href=\"#H65066665\">",
"     'Social transition'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H113274158\">",
"     'Overview of hormonal interventions for adolescents'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113274158\">",
"    <span class=\"h1\">",
"     OVERVIEW OF HORMONAL INTERVENTIONS FOR ADOLESCENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65066949\">",
"    <span class=\"h2\">",
"     Potential indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormonal interventions to suppress puberty",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    promote development of cross-gender secondary sexual characteristics may be warranted in gender-nonconforming youth whose desire to be of the other gender is persistent, consistent, and intensifies with the onset of pubertal changes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/4,9,13,29\">",
"     4,9,13,29",
"    </a>",
"    ]. Youth with intense feelings of gender dysphoria are at risk for adverse psychosocial outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12378?source=see_link&amp;anchor=H492231856#H492231856\">",
"     \"Overview of gender development and clinical presentation of gender nonconformity in children and adolescents\", section on 'Associated concerns'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional criteria for hormonal therapy may include adequate psychosocial support, understanding of the expected outcomes and medical and social risks and benefits of treatment, and ongoing mental health counseling. Hormonal treatment requires close collaboration with mental health providers. These requirements are outlined in the",
"    <a class=\"external\" href=\"file://www.endo-society.org/guidelines/final/upload/endocrine-treatment-of-transsexual-persons.pdf\">",
"     Endocrine Society Clinical Practice Guideline",
"    </a>",
"    and the",
"    <a class=\"external\" href=\"file://www.wpath.org/documents/Standards of Care_FullBook_1g-1.pdf\">",
"     World Professional Association for Transgender Health (WPATH) Standards of Care",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/2,13\">",
"     2,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65066871\">",
"    <span class=\"h2\">",
"     Counseling and consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with the initiation of any medical therapy, youth who are being considered for hormonal therapy for gender dysphoria and their parents must be fully informed of the potential risks and benefits of therapy before they can provide informed consent. They must understand which interventions are reversible, partially reversible, and irreversible, particularly with respect to future fertility. (See",
"    <a class=\"local\" href=\"#H231873\">",
"     'Suppression of endogenous puberty'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H231909\">",
"     'Treatment with cross-gender hormones'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Transgender youth who are treated with gonadotropin releasing hormone (GnRH) analogs to suppress endogenous puberty in Tanner stage 2 and then switched to cross-gender hormones will not develop sperm or oocytes that are viable for reproduction. It is critical that such youth understand that they will not be able to have their own biological children. Many adolescents are able to weigh the pros and cons of hormone therapy, including the potential impact on future fertility. In the authors&rsquo; experience, many transgender youth express that their desire for identity supersedes their desire for fertility. They clearly articulate plans to parent, but in their identified gender and using resources such as adoption or reproductive technologies.",
"   </p>",
"   <p>",
"    It is not clear how cross-gender hormones affect fertility in transgender youth who do not undergo pubertal suppression and initiate cross-gender hormones later in puberty. Although there may be irreversible loss of biologic reproductive potential, contraception is necessary to prevent unintended pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65066886\">",
"    <span class=\"h2\">",
"     Availability of care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormonal intervention for youth with gender dysphoria may be best performed in specialized centers with multidisciplinary teams that include medical and mental health professionals experienced in gender care [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition to offering coordinated services, many such centers are involved in long-term follow-up and research that will add to the limited body of evidence regarding outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, it can be difficult for gender-nonconforming adolescents and their families to find or access care with appropriately trained medical and mental health providers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. Multidisciplinary centers are available in a limited number of cities. Insurance coverage for medical interventions varies geographically and ability to pay out-of-pocket for services that are not covered by insurance may influence treatment options. Adolescents who are unable to afford or access hormonal interventions may decide to purchase hormones online or on the street and use them without medical supervision.",
"   </p>",
"   <p>",
"    When gender specialty centers are not available (which is more often than not), the World Professional Association for Transgender Health standards of care recommend that the clinician providing and monitoring hormonal treatment be well-versed in the relevant medical and psychological aspects of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/2\">",
"     2",
"    </a>",
"    ]. Such clinicians may be board-certified endocrinologists, but many gender specialists have other medical backgrounds with additional training in gender and sexual health. Without additional training and expertise, most primary care providers are uncomfortable with initial evaluations and starting youth on hormones. However, in order to improve access and patient-centered care, primary care providers are instrumental in coordinating care, providing referrals, and providing clinical and laboratory monitoring for patients receiving hormonal interventions. In addition, given the prior relationship with a child and family, primary care providers can be powerful role models for support, positive regard, and acceptance of transition for the youth and family members. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12378?source=see_link&amp;anchor=H462800773#H462800773\">",
"     \"Overview of gender development and clinical presentation of gender nonconformity in children and adolescents\", section on 'Role of the medical provider'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H231873\">",
"    <span class=\"h2\">",
"     Suppression of endogenous puberty",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65067200\">",
"    <span class=\"h3\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppression of endogenous puberty may be warranted for gender-nonconforming youth with persistent gender dysphoria that intensifies after the onset of puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/4,9,13,29\">",
"     4,9,13,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gender dysphoria that has been present since childhood and intensifies with the onset of puberty rarely subsides [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/4,6,28\">",
"     4,6,28",
"    </a>",
"    ]. In prospective follow-up of a cohort 70 gender dysphoric youth who underwent pubertal suppression, all of the patients elected to proceed with cross-gender hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Development of secondary sexual characteristics may result in increased body dysphoria and comorbid symptoms or associated concerns (eg, depression, anxiety, self-harm, suicidality, substance use, high risk sexual behaviors) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/1,29\">",
"     1,29",
"    </a>",
"    ]. Suppression of puberty may spare such youth the torment of continued development of the &ldquo;wrong&rdquo; sex characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suppression of puberty prevents the development of unwanted secondary sexual characteristics and &ldquo;buys time&rdquo; during which the youth can more fully explore his or her gender identity with a trained mental health professional. He or she can work with the mental health professional to make a thorough and informed decision about physical transition [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/31\">",
"     31",
"    </a>",
"    ]. Youth can also work with mental health providers to develop resiliency tools to help them cope with the stressors and challenges of hormonal transition in addition to the other challenges of adolescent development. The additional time and counseling also may help parents come to terms with a different future for their child than the one they may have envisioned [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential benefits of pubertal suppression include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/4,9,13,31,33\">",
"     4,9,13,31,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention of potentially traumatic events that may interfere with psychosocial functioning and well-being (eg, breast development,",
"      <span class=\"nowrap\">",
"       menarche/menses;",
"      </span>",
"      voice deepening, phallic growth, spontaneous erections, and unwanted male pattern hair growth)",
"     </li>",
"     <li>",
"      Clarification of gender identity and the degree of gender dysphoria",
"     </li>",
"     <li>",
"      Complete reversibility of the effects on secondary sexual characteristics; if the decision is made to discontinue GnRH analogs, the youth will progress through endogenous puberty normally&mdash;including retained ability to ovulate or produce sperm",
"     </li>",
"     <li>",
"      Opportunity to live in the phenotype of the affirmed gender (with concurrent social transition)",
"     </li>",
"     <li>",
"      Easier, less costly physical transition with improved physical outcome for patients who decide to proceed with cross-gender hormone therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      surgical reassignment than if they progress through endogenous puberty",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limited evidence from observational studies suggests that suppression of endogenous puberty may help to alleviate psychosocial distress in gender dysphoric youth. In prospective follow-up of a cohort 70 gender dysphoric youth, behavioral and emotional problems, depressive symptoms, and general functioning improved after treatment with GnRH analogs to suppress puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/7\">",
"     7",
"    </a>",
"    ]. However, pubertal suppression did not alleviate gender dysphoria and all of the treated patients elected to proceed with cross-gender hormones. In another observational study, all patients who underwent pubertal suppression with GnRH analogs were satisfied with their lack of pubertal development; all of those who were eligible for cross-hormone treatment chose to proceed; no adverse effects were noted; and no patients took street hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Longer-term follow-up is necessary to examine whether gender dysphoric adolescents who underwent pubertal suppression with GnRH analogs followed by cross-gender hormones will be able to maintain their relatively good functioning in their adult years after gender reassignment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H231880\">",
"    <span class=\"h3\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Endocrine Society guidelines suggest that suppression of pubertal hormones (for appropriate patients) should begin when patients first exhibit physical signs of puberty and the onset of puberty is confirmed by pubertal levels of luteinizing hormone (LH), testosterone,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    estradiol depending on genotypic sex [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/13\">",
"     13",
"    </a>",
"    ]. The Endocrine Society guidelines suggest allowing some pubertal development to confirm gender dysphoria [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/13\">",
"     13",
"    </a>",
"    ]. However, some gender specialty centers initiate GnRH analogs as early as possible in puberty to avoid undesired and emotionally painful genotypic pubertal development. Administration of GnRH analogs before Tanner stage 2 provides no benefit and is unnecessarily expensive.",
"   </p>",
"   <p>",
"    The onset of puberty is best determined by physical examination. For genotypic females, puberty usually begins with breast budding (",
"    <a class=\"graphic graphic_picture graphicRef72038 \" href=\"UTD.htm?10/43/10932\">",
"     picture 1A",
"    </a>",
"    ). For genotypic males, puberty begins with testicular enlargement (testicular volume &gt;4 mL) (",
"    <a class=\"graphic graphic_picture graphicRef80005 \" href=\"UTD.htm?32/26/33187\">",
"     picture 1C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link\">",
"     \"Normal puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The onset of puberty can be confirmed by an increase in gonadotropin levels (LH and follicle stimulating hormone [FSH]) and sex steroid levels (estradiol or testosterone) above prepubertal levels (which may vary from lab to lab). Ultrasensitive assays are best to distinguish prepubertal from early pubertal levels of gonadotropins.",
"   </p>",
"   <p>",
"    Although it is ideal to begin GnRH analogs at early Tanner 2, not all youth present for medical care at or before this stage of puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/4\">",
"     4",
"    </a>",
"    ]. If initiated at Tanner stage 3 or 4 (",
"    <a class=\"graphic graphic_picture graphicRef72038 graphicRef79782 graphicRef80005 \" href=\"UTD.htm?22/27/22970\">",
"     picture 1A-C",
"    </a>",
"    ), GnRH analogs may prevent continued progression of puberty, maintain androgynous physical features, cause some regression of secondary sexual characteristics, stop menses or erections, and provide psychological relief for a patient who is distressed by cis-gendered development [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/7,13,31\">",
"     7,13,31",
"    </a>",
"    ]. However, GnRH analogs provide little benefit for patients who present in late puberty, when irreversible secondary sexual characteristics are already well developed (eg, breasts, Adam&rsquo;s apple, voice deepening, etc). For such patients, cross-gender hormone therapy may be more appropriate. (See",
"    <a class=\"local\" href=\"#H231909\">",
"     'Treatment with cross-gender hormones'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H231888\">",
"    <span class=\"h3\">",
"     Regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppression of puberty can be achieved with the use of GnRH analogs, antiandrogens, antiestrogens, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/49/36631?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/13,34,35\">",
"     13,34,35",
"    </a>",
"    ]. GnRH analogs are usually preferred because of their efficacy, safety profile, and clinical experience in treating children with precocious puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4889?source=see_link&amp;anchor=H23809007#H23809007\">",
"     \"Treatment of precocious puberty\", section on 'GnRH agonist treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The availability of GnRH analogs and coverage by insurance varies geographically. Medication regimens are not standardized. The protocol suggested in the",
"    <a class=\"external\" href=\"file://www.endo-society.org/guidelines/final/upload/endocrine-treatment-of-transsexual-persons.pdf\">",
"     Endocrine Society Clinical Practice Guideline",
"    </a>",
"    was developed by the Center of Expertise on Gender Dysphoria (formerly the Amsterdam Gender Clinic) and is endorsed by the Australasian Paediatric Endocrine Group [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/13,27,31,39\">",
"     13,27,31,39",
"    </a>",
"    ]. This protocol and others adapted from it have demonstrated suppression of puberty without adverse effects in small cohorts of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GnRH analogs may be administered in a variety of forms, including injections and implants (",
"    <a class=\"graphic graphic_table graphicRef72979 \" href=\"UTD.htm?41/16/42252\">",
"     table 3",
"    </a>",
"    ). In our experience, most adolescents start with intramuscular injections monthly or once every three months. The dose is titrated to adequately suppress puberty by patient report, physical examination,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laboratory values. (See",
"    <a class=\"local\" href=\"#H231902\">",
"     'Monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    GnRH analogs ideally are continued concurrently with cross-gender hormones until patients can receive gonadectomies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/13\">",
"     13",
"    </a>",
"    ]. However, they usually are discontinued earlier. Prolonged suppressive therapy with GnRH analogs is expensive, may not be covered by insurance, and may be unaffordable or unavailable for patients. An alternative regimen for transgender youth may be to discontinue GnRH analogs after one to two years and initiate cross-gender therapy. Timing of cross-gender hormone administration and puberty in the youth&rsquo;s identified gender should be timed with puberty initiation and development consistent with their peers. (See",
"    <a class=\"local\" href=\"#H231923\">",
"     'Timing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86770922\">",
"    <span class=\"h3\">",
"     Potential adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no studies of the long-term effects of GnRH analogs when used to suppress puberty among gender-nonconforming youth. It is unclear if earlier transition and experience of puberty in their identified gender will impact risks and health outcomes in the future.",
"   </p>",
"   <p>",
"    Pubertal suppression alters the timing of the pubertal growth spurt and delays fusion of the growth plates, which may affect adult height [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/31\">",
"     31",
"    </a>",
"    ]. It is important to monitor height every three months during pubertal suppression to permit interventions to prevent unacceptably tall stature for natal males who are transitioning to female and unacceptably short stature for natal females who are transitioning to male. (See",
"    <a class=\"local\" href=\"#H231902\">",
"     'Monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Decreased bone mineral density is a potential risk because accretion of bone mineral density is suspended during GnRH analog therapy without cross-gender hormones. However, in children treated with GnRH analogs for precocious puberty, bone mass is regained after cessation of treatment and peak bone mass is normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4889?source=see_link&amp;anchor=H23809028#H23809028\">",
"     \"Treatment of precocious puberty\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, in observational studies of gender dysphoric youth treated with GnRH analogs, after cross-gender hormones were added to the treatment regimen, bone mineral density was restored and peak bone mineral density was unaffected (for those treated with testosterone as well as those treated with estrogen) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. However, because there is limited information about long-term bone health among gender dysphoric youth who are treated with GnRH analogs and cross-gender hormones, monitoring of bone density during treatment may be warranted. (See",
"    <a class=\"local\" href=\"#H231902\">",
"     'Monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Genotypic females who are started on GnRH analogs well into puberty may experience hot flashes and other signs and symptoms related to rapid withdrawal of sex hormones (eg, withdrawal bleeding and disruption of menstrual cycles) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients and parents should be alerted to potential irritability, depression, and other symptoms of menopause [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/42\">",
"     42",
"    </a>",
"    ]. Patients with significant mental health concerns must be monitored closely. Genotypic males may complain of fatigue and decreased strength [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H231902\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Youth undergoing pubertal suppression must be monitored at regular intervals to assure that the medications are continuing to suppress the patient&rsquo;s endogenous hormones without adversely affecting growth or bone density. Monitoring parameters may include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/13,31\">",
"     13,31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Growth (height, weight) every three months",
"     </li>",
"     <li>",
"      Endogenous sex hormone levels (estradiol or testosterone) and gonadotropin levels (LH and FSH) at baseline and every three months to assure adequate suppression into the prepubertal range (which may vary from lab to lab); if the gonadal axis is not completely suppressed, the interval between GnRH analog injections may need to be shortened or the dose increased",
"     </li>",
"     <li>",
"      Bone age (radiograph of left hand) yearly (to monitor bone age advancement) for youth with concerns about optimizing height",
"     </li>",
"     <li>",
"      Bone mineral density at baseline and annually for youth who are at risk for low bone mineral density and will be on GnRH analogs for more than two years; addition of cross-gender hormones may be warranted if bone density significantly decreases",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H231909\">",
"    <span class=\"h2\">",
"     Treatment with cross-gender hormones",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176168012\">",
"    <span class=\"h3\">",
"     Rationale and eligibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with cross-gender hormones is necessary to induce cross-gender puberty and to maintain cross-gender phenotypic appearance. Some of the phenotypic changes that are attained with cross-gender hormone therapy are reversible and others are not. (See",
"    <a class=\"local\" href=\"#H231937\">",
"     'Male-to-female'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H231944\">",
"     'Female-to-male'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Adolescents may be eligible for cross-gender hormone therapy if they [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/2,13\">",
"     2,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Have adequate psychosocial support",
"     </li>",
"     <li>",
"      Understand the expected outcomes and the medical and social risks and benefits",
"     </li>",
"     <li>",
"      Have stable mental health",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mental health counseling and support",
"     </li>",
"     <li>",
"      Have consolidated their gender identity through social transition or psychotherapy",
"     </li>",
"     <li>",
"      Will take cross-gender hormones in a responsible manner",
"     </li>",
"     <li>",
"      Have no contraindications to cross-gender hormones (ie, for transgender females [genotypic males]: hypertension, liver dysfunction, conditions that cause excessive blood clotting, estrogen-dependent tumors; for transgender males [genotypic females]: polycythemia, liver dysfunction); these contraindications are uncommon in adolescents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These requirements are outlined in the",
"    <a class=\"external\" href=\"file://www.endo-society.org/guidelines/final/upload/endocrine-treatment-of-transsexual-persons.pdf\">",
"     Endocrine Society Clinical Practice Guideline",
"    </a>",
"    and the",
"    <a class=\"external\" href=\"file://www.wpath.org/documents/Standards of Care_FullBook_1g-1.pdf\">",
"     World Professional Association for Transgender Health (WPATH) Standards of Care",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/2,13\">",
"     2,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H231923\">",
"    <span class=\"h3\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision about when to initiate cross-gender hormones in adolescents must be individualized. For adolescents who have undergone pubertal suppression, most protocols recommend initiation of cross-gender hormones to induce cross-gender puberty at age 16 years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]. However, age 16 years is an arbitrary threshold that corresponds to the legal age of consent in some European countries. Earlier initiation may be warranted for patients in whom gender identity is well established and stable at an early age or transgender females with unacceptably tall stature on a case-by-case basis after review of the risks and benefits with the youth and parents [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/1,4,31\">",
"     1,4,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initiation of cross-gender hormones before age 16 years (ie, at a time similar to pubertal onset in age-matched peers) may have psychosocial benefits. Given the importance of peer congruence during the high-school years, it is reasonable to assume that a 16-year-old with the sexual development of a 10-year-old may suffer some psychologic distress&mdash;although this has not been formally evaluated in clinical studies.",
"   </p>",
"   <p>",
"    Initiation of cross-gender hormones before age 16 years also can decrease the financial burden for patients and families if suppression of puberty with GnRH is discontinued when cross-gender hormones are started. In the United States (where",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/11/9398?source=see_link\">",
"     triptorelin",
"    </a>",
"    is not available for pubertal suppression), suppression of puberty with GnRH analogs is more expensive than cross-gender hormones, and may not be covered by insurance, whereas cross-gender hormones often are covered by insurance plans or available at the substantially discounted medication programs offered by various national pharmacies.",
"   </p>",
"   <p>",
"    Adolescents with gender dysphoria who have not undergone pubertal suppression may begin cross-gender hormone therapy when they meet the eligibility and readiness criteria described above [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/1,4,13\">",
"     1,4,13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H176168012\">",
"     'Rationale and eligibility'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If cross-gender hormone therapy is started after puberty is complete or near complete in transgender females the administration of estrogen and androgen blockers will not affect voice pitch, laryngeal prominence (Adam&rsquo;s apple), height, or growth of facial hair [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/1\">",
"     1",
"    </a>",
"    ]. Similarly, if cross-gender hormone therapy is started after puberty is complete or near complete in transgender males, the administration of testosterone will not reduce the size of the breasts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H231937\">",
"    <span class=\"h3\">",
"     Male-to-female",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenous estrogen is necessary for feminization of genotypic males. The addition of androgen blockers (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/0/17414?source=see_link\">",
"     spironolactone",
"    </a>",
"    ) assists in reducing testosterone activity.",
"   </p>",
"   <p>",
"    The primary aims of estrogen therapy are (",
"    <a class=\"graphic graphic_table graphicRef54189 \" href=\"UTD.htm?27/61/28636\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Development of breasts (irreversible) and female fat distribution pattern (reversible)",
"     </li>",
"     <li>",
"      Softening of the skin (reversible)",
"     </li>",
"     <li>",
"      Maintenance of a higher pitch voice (provided that puberty was blocked; estrogen will not cause a voice change if the voice has already deepened)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Decrease/avoidance",
"      </span>",
"      of male pattern body and facial hair (partially reversible)",
"     </li>",
"     <li>",
"      Decrease in testicular mass (irreversible)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cross-gender hormone regimens to induce puberty and to maintain cross-gender sexual characteristics are provided in the",
"    <a class=\"external\" href=\"file://www.endo-society.org/guidelines/final/upload/endocrine-treatment-of-transsexual-persons.pdf\">",
"     Endocrine Society Clinical Practice Guideline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/13\">",
"     13",
"    </a>",
"    ]. These regimens assume continued treatment with GnRH analogs. For patients who are not continuing GnRH analogs, the dose of estrogen will need to be increased (approximately doubled) to achieve development of female secondary sexual characteristics and suppress endogenous testosterone. The estrogen dose should be increased gradually to prevent striae and abnormal breast shape [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estrogen is available in oral, sublingual, topical (patch), or intramuscular preparations. Oral17&beta;-estradiol is most commonly used because blood levels can be monitored and it is associated with a lower risk of thromboembolic events than other estrogens (eg, ethinyl estradiol) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/43\">",
"     43",
"    </a>",
"    ]. Many providers suggest that the oral 17&beta;-estradiol preparation be taken sublingually. In theory, sublingual administration should bypass first-pass hepatic metabolism, which may increase levels and decrease the risk of adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]; however, this hypothesis has not been formally studied. However, some adolescents prefer intramuscular injections of 17&beta;-estradiol every two weeks.",
"   </p>",
"   <p>",
"    The frequency of adverse effects has not been reported in case series of adolescents receiving cross-gender hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/4,6,9\">",
"     4,6,9",
"    </a>",
"    ]. Adverse effects described in observational studies of adult male-to-female transsexuals include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/1,13,34,46-48\">",
"     1,13,34,46-48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Development of deep venous thrombosis",
"     </li>",
"     <li>",
"      Hyperprolactinemia",
"     </li>",
"     <li>",
"      Prolactinoma (in case reports)",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Elevated liver enzymes",
"     </li>",
"     <li>",
"      Decreased libido",
"     </li>",
"     <li>",
"      Increased risk of breast cancer (in case reports)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adverse effects of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/0/17414?source=see_link\">",
"     spironolactone",
"    </a>",
"    include hyperkalemia and decreased blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H231944\">",
"    <span class=\"h3\">",
"     Female-to-male",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenous testosterone is necessary for masculinization of genotypic females. The primary aims of testosterone therapy are (",
"    <a class=\"graphic graphic_table graphicRef75101 \" href=\"UTD.htm?6/38/6764\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Suppression of menstruation and breast development (reversible)",
"     </li>",
"     <li>",
"      Clitoral enlargement (irreversible)",
"     </li>",
"     <li>",
"      Deepening of the voice (irreversible)",
"     </li>",
"     <li>",
"      Development of male pattern body and facial hair (partially reversible)",
"     </li>",
"     <li>",
"      Increase in lean muscle mass (reversible)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cross-gender hormone regimens to induce puberty and to maintain cross-gender sexual characteristics are provided in the",
"    <a class=\"external\" href=\"file://www.endo-society.org/guidelines/final/upload/endocrine-treatment-of-transsexual-persons.pdf\">",
"     Endocrine Society Clinical Practice Guideline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/13\">",
"     13",
"    </a>",
"    ]. These regimens assume continued treatment with GnRH analogs. For patients who are not continuing GnRH analogs, the dose of testosterone will need to be increased (approximately doubled) to achieve development of male secondary sexual characteristics and suppress endogenous estrogen.",
"   </p>",
"   <p>",
"    Testosterone is available as an intramuscular injection, topical patches, topical gels, and orally (in some countries, but not the United States). It is most commonly given intramuscularly, on a weekly or biweekly schedule. Subcutaneous administration is used by many providers because it is better tolerated, less painful, and as efficacious as intramuscular injection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/49\">",
"     49",
"    </a>",
"    ]. Oral and topical preparations have unpredictable absorption, which makes dosing and monitoring difficult. Another disadvantage of topical preparations is that they may be inadvertently absorbed by another person through skin-to-skin contact, potentially causing unintended masculinization.",
"   </p>",
"   <p>",
"    <br/>",
"    Transgender males who are starting cross-gender hormones in early or middle adolescence may not necessarily desire profuse body hair, so it is prudent to increase the dose slowly. On the other hand, too slow or too low a dose may not be sufficient to suppress endogenous estrogen and may lead to undesired menstruation or breast development.",
"   </p>",
"   <p>",
"    The frequency of adverse effects has not been reported in case series of adolescents receiving cross-gender hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/4,6,9\">",
"     4,6,9",
"    </a>",
"    ]. Adverse effects of testosterone therapy may include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/1,13,34,46-48\">",
"     1,13,34,46-48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hyperlipidemia",
"     </li>",
"     <li>",
"      Polycythemia",
"     </li>",
"     <li>",
"      Male pattern baldness",
"     </li>",
"     <li>",
"      Acne",
"     </li>",
"     <li>",
"      Infertility",
"     </li>",
"     <li>",
"      Elevated liver enzymes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transgender males (ie, genotypic females) who are having receptive vaginal sex with people with penises must understand that testosterone administration will not prevent pregnancy. Condom use is recommended to prevent pregnancy as well as sexually transmitted infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113274249\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing cross-hormone therapy should return for a physical examination to assess feminization or masculinization and laboratory tests every three months for the first year of treatment. If the patient is progressing well into their transgender puberty and having no untoward side effects, providers may decrease the frequency to every six months.",
"   </p>",
"   <p>",
"    During the induction of puberty, the following examinations and lab tests are recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Height, weight, breast development (in transgender females) &ndash; every three months during the first year of treatment",
"     </li>",
"     <li>",
"      Estradiol, testosterone &ndash; every three months during the first year of treatment",
"     </li>",
"     <li>",
"      Renal function, liver function, lipids, glucose, insulin, glycosylated hemoglobin &ndash; yearly",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Following induction of cross-gender puberty, the protocols for monitoring transsexual patients are provided in the Tables (",
"    <a class=\"graphic graphic_table graphicRef67967 graphicRef78811 \" href=\"UTD.htm?19/5/19549\">",
"     table 6A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H231967\">",
"    <span class=\"h1\">",
"     SURGICAL INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical sex reassignment generally is undertaken after 18 years of age. It is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8602?source=see_link&amp;anchor=H27#H27\">",
"     \"Treatment of transsexualism\", section on 'Surgical sex reassignment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233854\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resources for patients, families, and providers include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.childrensnational.org/departmentsandprograms/default.aspx?Id=6178&amp;Type=Program&amp;Name=Gender%20and%20Sexuality%20Psychosocial%20Programs\">",
"       Children's National Medical Center Gender and Sexuality Psychosocial Programs",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.genderspectrum.org/education\">",
"       Gender Spectrum",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.mchlibrary.info/families/frb_LGBTQ.html\">",
"       Maternal &amp; Child Health Library at Georgetown University",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.transyouthequality.org/\">",
"       Trans Youth Equality Foundation",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://imatyfa.org/\">",
"       TransYouth Family Allies",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://transhealth.ucsf.edu/trans?page=lib0002\">",
"       University of California, San Francisco Center of Excellence for Transgender Health",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://transhealth.vch.ca/resources/careguidelines.html\">",
"       Vancouver Coastal Health Transgender Health Program",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.wpath.org/\">",
"       World Professional Association for Transgender Health",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Books for children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?10/25/10650/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It&rsquo;s Perfectly Normal: Changing Bodies, Growing Up, Sex and Sexual Health by Robie H. Harris and Michael Emberley (Candlewick 2009)",
"     </li>",
"     <li>",
"      Changing Bodies, Changing Lives: Expanded Third Edition: A Book for Teens on Sex and Relationships by Ruth Bell (Three Rivers Press 1998)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233773\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The information provided in this topic is intended to allow primary care providers to educate and support patients and families of patients with gender nonconformity and to coordinate care, provide referrals, and monitor patients receiving care from specialists. (See",
"      <a class=\"local\" href=\"#H231831\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management for gender-nonconforming youth is determined on a case-by-case basis. The safety and well-being of the youth and his or her family members is foremost. (See",
"      <a class=\"local\" href=\"#H231838\">",
"       'Guiding principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment options may be influenced by cultural differences, opinions of health professionals, insurance coverage, and availability of services. Mental health interventions may include redirection, wait-and-see, and affirmation. Reparative therapies, which claim to &ldquo;cure&rdquo; transgender identity, are considered unhelpful and potentially harmful by most professional organizations. (See",
"      <a class=\"local\" href=\"#H83439611\">",
"       'Mental health interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Phenotypic interventions include social transition (ie, living partially or completely in the preferred gender role by adapting hairstyle, clothing, pronouns, and possibly a new name) and hormonal interventions to suppress endogenous puberty",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      alter secondary sexual characteristics. (See",
"      <a class=\"local\" href=\"#H65066672\">",
"       'Hormonal interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the unpredictability of the trajectory of gender nonconformity in prepubertal children, it seems reasonable for the primary care provider to offer education, support, and referral to mental health providers as indicated for those with evidence of gender dysphoria; coexisting anxiety, depression, or suicidality; or significant interpersonal conflicts with peers (eg, bullying) or parents. (See",
"      <a class=\"local\" href=\"#H25477379\">",
"       'Approach in prepubertal children'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12378?source=see_link&amp;anchor=H462800773#H462800773\">",
"       \"Overview of gender development and clinical presentation of gender nonconformity in children and adolescents\", section on 'Role of the medical provider'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gender dysphoria that persists through the onset of puberty or is increased at the onset of puberty is unlikely to subside. For adolescents with gender dysphoria, most gender specialists suggest a supportive, affirming approach with an interdisciplinary team that includes medical and mental health specialists. The management needs and goals differ from adolescent to adolescent. (See",
"      <a class=\"local\" href=\"#H25477701\">",
"       'Approach in pubertal children and adolescents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To allow time for the adolescent to develop the maturity necessary to make a thorough and informed decision about permanent physical changes, medical interventions generally progress from reversible (eg, social transition, pubertal suppression), to partially reversible interventions (eg, cross-gender hormones), to irreversible interventions (eg, surgical interventions). (See",
"      <a class=\"local\" href=\"#H25477701\">",
"       'Approach in pubertal children and adolescents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H65066665\">",
"       'Social transition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H113274158\">",
"       'Overview of hormonal interventions for adolescents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hormonal interventions to suppress puberty",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      promote development of cross-gender secondary sexual characteristics may be warranted for gender-nonconforming youth whose desire to be of the other gender is persistent, consistent, and intensifies with the onset of pubertal changes. Youth with intense feelings of gender dysphoria are at risk for adverse psychosocial outcomes. (See",
"      <a class=\"local\" href=\"#H65066949\">",
"       'Potential indications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12378?source=see_link&amp;anchor=H492231856#H492231856\">",
"       \"Overview of gender development and clinical presentation of gender nonconformity in children and adolescents\", section on 'Associated concerns'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/1\">",
"      Olson J, Forbes C, Belzer M. Management of the transgender adolescent. Arch Pediatr Adolesc Med 2011; 165:171.",
"     </a>",
"    </li>",
"    <li>",
"     World Professional Association for Transgender Health (WPATH). WPATH Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People, 7th Version. Available at: www.wpath.org/documents/Standards%20of%20Care_FullBook_1g-1.pdf (Accessed on November 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/3\">",
"      Smith YL, Van Goozen SH, Kuiper AJ, Cohen-Kettenis PT. Sex reassignment: outcomes and predictors of treatment for adolescent and adult transsexuals. Psychol Med 2005; 35:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/4\">",
"      Spack NP, Edwards-Leeper L, Feldman HA, et al. Children and adolescents with gender identity disorder referred to a pediatric medical center. Pediatrics 2012; 129:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/5\">",
"      Cohen-Kettenis PT, Steensma TD, de Vries AL. Treatment of adolescents with gender dysphoria in the Netherlands. Child Adolesc Psychiatr Clin N Am 2011; 20:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/6\">",
"      de Vries AL, Cohen-Kettenis PT. Clinical management of gender dysphoria in children and adolescents: the Dutch approach. J Homosex 2012; 59:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/7\">",
"      de Vries AL, Steensma TD, Doreleijers TA, Cohen-Kettenis PT. Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study. J Sex Med 2011; 8:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/8\">",
"      Hewitt JK, Paul C, Kasiannan P, et al. Hormone treatment of gender identity disorder in a cohort of children and adolescents. Med J Aust 2012; 196:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/9\">",
"      Edwards-Leeper L, Spack NP. Psychological evaluation and medical treatment of transgender youth in an interdisciplinary \"Gender Management Service\" (GeMS) in a major pediatric center. J Homosex 2012; 59:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/10\">",
"      Cohen-Kettenis PT, van Goozen SH. Sex reassignment of adolescent transsexuals: a follow-up study. J Am Acad Child Adolesc Psychiatry 1997; 36:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/11\">",
"      Smith YL, van Goozen SH, Cohen-Kettenis PT. Adolescents with gender identity disorder who were accepted or rejected for sex reassignment surgery: a prospective follow-up study. J Am Acad Child Adolesc Psychiatry 2001; 40:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/12\">",
"      Drescher J, Byne W. Gender dysphoric/gender variant (GD/GV) children and adolescents: summarizing what we know and what we have yet to learn. J Homosex 2012; 59:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/13\">",
"      Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94:3132.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Child and Adolescent Psychiatry. Practice parameter on gay, lesbian or bisexual sexual orientation, gender-nonconformity, and gender discordance in children and adolescents file://www.aacap.org/galleries/PracticeParameters/glbt_practice_parameter_june_2012.pdf (Accessed on November 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/15\">",
"      Spack N. Transgenderism. Med Ethics (Burlingt Mass) 2005; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     de Vries AL, Cohen-Kettenis PT, Delemarre-Van de Waal, H. Caring for transgender adolescents in BC: Suggested guidelines transhealth.vch.ca/resources/library/tcpdocs/guidelines-adolescent.pdf (Accessed on October 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/17\">",
"      Shechner T. Gender identity disorder: a literature review from a developmental perspective. Isr J Psychiatry Relat Sci 2010; 47:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/18\">",
"      Hill DB, Menvielle E, Sica KM, Johnson A. An affirmative intervention for families with gender variant children: parental ratings of child mental health and gender. J Sex Marital Ther 2010; 36:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/19\">",
"      Tuerk C. Considerations for affirming gender nonconforming boys and their families: new approaches, new challenges. Child Adolesc Psychiatr Clin N Am 2011; 20:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/20\">",
"      Gender Identity Disorder in Young Boys: A parent- and peer-based treatment protocol. Clin Child Psychol Psychiatry 2002; 7:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/21\">",
"      Rekers GA, Lovaas OI. Behavioral treatment of deviant sex-role behaviors in a male child. J Appl Behav Anal 1974; 7:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/22\">",
"      Rekers GA, Lovaas OI, Low B. The behavioral treatment of a \"transsexual\" preadolescent boy. J Abnorm Child Psychol 1974; 2:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/23\">",
"      Society for Adolescent Health and Medicine. Recommendations for promoting the health and well-being of lesbian, gay, bisexual, and transgender adolescents: a position paper of the society for adolescent health and medicine. J Adolesc Health 2013; 52:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/24\">",
"      Steensma TD, van der Ende J, Verhulst FC, Cohen-Kettenis PT. Gender Variance in Childhood and Sexual Orientation in Adulthood: A Prospective Study. J Sex Med 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/25\">",
"      Zucker KJ. On the \"natural history\" of gender identity disorder in children. J Am Acad Child Adolesc Psychiatry 2008; 47:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/26\">",
"      Steensma TD, Cohen-Kettenis PT. Gender transitioning before puberty? Arch Sex Behav 2011; 40:649.",
"     </a>",
"    </li>",
"    <li>",
"     Perrin EC. Sexual Orientation in Child and Adolescent Health Care, Springer, New York 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/28\">",
"      Steensma TD, Biemond R, de Boer F, Cohen-Kettenis PT. Desisting and persisting gender dysphoria after childhood: a qualitative follow-up study. Clin Child Psychol Psychiatry 2011; 16:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/29\">",
"      Zucker KJ. The DSM diagnostic criteria for gender identity disorder in children. Arch Sex Behav 2010; 39:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/30\">",
"      Cohen-Kettenis PT, van Goozen SH. Pubertal delay as an aid in diagnosis and treatment of a transsexual adolescent. Eur Child Adolesc Psychiatry 1998; 7:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/31\">",
"      Delemarre-van de Waal, Cohen-Kettenis PT. Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects. Eur J Endocrinol. 2006; 155 Suppl 1:S131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/32\">",
"      Malpas J. Between pink and blue: a multi-dimensional family approach to gender nonconforming children and their families. Fam Process 2011; 50:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/33\">",
"      Manasco PK, Pescovitz OH, Feuillan PP, et al. Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty. J Clin Endocrinol Metab 1988; 67:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/34\">",
"      Menvielle E, Gomez-Lobo V. Management of children and adolescents with gender dysphoria. J Pediatr Adolesc Gynecol 2011; 24:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/35\">",
"      Meyer WJ 3rd. Gender identity disorder: an emerging problem for pediatricians. Pediatrics 2012; 129:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/36\">",
"      Jain J, Dutton C, Nicosia A, et al. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. Contraception 2004; 70:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/37\">",
"      Mieszczak J, Eugster EA. Treatment of precocious puberty in McCune-Albright syndrome. Pediatr Endocrinol Rev 2007; 4 Suppl 4:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/38\">",
"      Richman RA, Underwood LE, French FS, Van Wyk JJ. Adverse effects of large doses of medroxyprogesterone (MPA) in idiopathic isosexual precocity. J Pediatr 1971; 79:963.",
"     </a>",
"    </li>",
"    <li>",
"     Australasian Paediatric Endocrine Group. Gender Identity Disorder Guidelines. file://www.apeg.org.au/Portals/0/guidelines.pdf (Accessed on October 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/40\">",
"      Delemarre-van DE Waal, Cohen-Kettenis PT. Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects. Eur J Endocrinol 2006; 155:S131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/41\">",
"      Cohen-Kettenis PT, Schagen SE, Steensma TD, et al. Puberty suppression in a gender-dysphoric adolescent: a 22-year follow-up. Arch Sex Behav 2011; 40:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/42\">",
"      Kiesel LA, Rody A, Greb RR, Szil&aacute;gyi A. Clinical use of GnRH analogues. Clin Endocrinol (Oxf) 2002; 56:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/43\">",
"      Toorians AW, Thomassen MC, Zweegman S, et al. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metab 2003; 88:5723.",
"     </a>",
"    </li>",
"    <li>",
"     Hormone administration. UCSF Center of Excellence for Trandgender Health. file://transhealth.ucsf.edu/trans?page=protocol-hormones (Accessed on October 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/45\">",
"      Price TM, Blauer KL, Hansen M, et al. Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17 beta-estradiol. Obstet Gynecol 1997; 89:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/46\">",
"      Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab 2003; 88:3467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/47\">",
"      Meyer WJ 3rd, Webb A, Stuart CA, et al. Physical and hormonal evaluation of transsexual patients: a longitudinal study. Arch Sex Behav 1986; 15:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/25/10650/abstract/48\">",
"      Tangpricha V, Ducharme SH, Barber TW, Chipkin SR. Endocrinologic treatment of gender identity disorders. Endocr Pract 2003; 9:12.",
"     </a>",
"    </li>",
"    <li>",
"     Spack N. Personal Communication. 2011.",
"    </li>",
"    <li>",
"     Edwards-Leeper L, Spack NP. Gender identity disorder. In: The Zuckerman Parker Handbook of Developmental and Behavioral Pediatrics for Primary Care, 3rd, Augustyn M, Zuckerman B, Caronna EB.  (Eds), 2011. p.229.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86771 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-DA858D2583-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_25_10650=[""].join("\n");
var outline_f10_25_10650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H233773\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25477371\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H231831\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H231838\">",
"      GUIDING PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25477604\">",
"      TYPES OF INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83439611\">",
"      Mental health interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83439674\">",
"      Phenotypic interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H65066665\">",
"      - Social transition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H65066672\">",
"      - Hormonal interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H191437845\">",
"      - Surgical interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25477379\">",
"      APPROACH IN PREPUBERTAL CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25477701\">",
"      APPROACH IN PUBERTAL CHILDREN AND ADOLESCENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H113274158\">",
"      OVERVIEW OF HORMONAL INTERVENTIONS FOR ADOLESCENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H65066949\">",
"      Potential indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H65066871\">",
"      Counseling and consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H65066886\">",
"      Availability of care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H231873\">",
"      Suppression of endogenous puberty",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H65067200\">",
"      - Rationale",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H231880\">",
"      - Timing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H231888\">",
"      - Regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86770922\">",
"      - Potential adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H231902\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H231909\">",
"      Treatment with cross-gender hormones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H176168012\">",
"      - Rationale and eligibility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H231923\">",
"      - Timing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H231937\">",
"      - Male-to-female",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H231944\">",
"      - Female-to-male",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H113274249\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H231967\">",
"      SURGICAL INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H233854\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H233773\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/86771\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/86771|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/43/10932\" title=\"picture 1A\">",
"      Sexual maturity rating of breast development in girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/33/30227\" title=\"picture 1B\">",
"      Sexual maturity rating of pubic hair in girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/26/33187\" title=\"picture 1C\">",
"      Sexual maturity rating of pubic hair in boys",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/86771|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/1/10269\" title=\"table 1\">",
"      Gender nonconformity terminology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/29/13789\" title=\"table 2\">",
"      Gender nonconformity transition plan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/16/42252\" title=\"table 3\">",
"      GnRH agonists for GDPP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/61/28636\" title=\"table 4\">",
"      Feminizing effects in male-to-female transsexual persons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/38/6764\" title=\"table 5\">",
"      Masculinizing effects in female-to-male transsexual persons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/43/43707\" title=\"table 6A\">",
"      Monitoring of MTF transsexual persons on cross-hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/1/24604\" title=\"table 6B\">",
"      Monitoring of FTM transsexual persons on cross-hormone therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12378?source=related_link\">",
"      Overview of gender development and clinical presentation of gender nonconformity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4889?source=related_link\">",
"      Treatment of precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8602?source=related_link\">",
"      Treatment of transsexualism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_25_10651="Skin thermal relaxation time";
var content_f10_25_10651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Thermal relaxation times",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Target",
"       </td>",
"       <td class=\"subtitle1\">",
"        Thermal relaxation time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        200 &micro;m hair follicle",
"       </td>",
"       <td>",
"        20 msec",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        100 &micro;m port wine stain blood vessel",
"       </td>",
"       <td>",
"        5 msec",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50 &micro;m blood vessel",
"       </td>",
"       <td>",
"        1 msec",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50 &micro;m of epidermis",
"       </td>",
"       <td>",
"        1 msec",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7 &micro;m erythrocyte",
"       </td>",
"       <td>",
"        20 &micro;sec",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 &micro;m melanosome",
"       </td>",
"       <td>",
"        1 &micro;sec",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.1 &micro;m tattoo particle",
"       </td>",
"       <td>",
"        10 nsec",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_25_10651=[""].join("\n");
var outline_f10_25_10651=null;
var title_f10_25_10652="Signs symptoms lead toxicity";
var content_f10_25_10652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Signs and symptoms of lead toxicity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Lowest exposure: Impaired abilities (patients may be asymptomatic)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Decreased learning and memory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Decreased verbal ability",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Early signs of hyperactivity or ADHD",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lowered IQ",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Impaired speech and hearing functions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Low exposure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Myalgia or paresthesia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mild fatigue",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Irritability",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lethargy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Occasional abdominal discomfort",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Moderate exposure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Arthralgia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       General fatigue",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Difficulty concentrating",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Muscular exhaustibility",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tremor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Headache",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diffuse abdominal pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vomiting",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Weight loss",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Constipation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       High exposure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Paresis or paralysis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Encephalopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       May abruptly lead to seizures, changesin consciousness, coma, and death",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lead line (blue-black) on gingival tissue",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Colic (intermittent, severe abdominal cramps)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     www.atsdr.cdc.gov/csem/lead/pbpatient_evaluation2.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_25_10652=[""].join("\n");
var outline_f10_25_10652=null;
var title_f10_25_10653="NSAID lowers GFR in cirrhosis";
var content_f10_25_10653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Graph showing reduction in creatinine clearance after NSAIDs in patients with hepatic cirrhosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 234px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Reduction in GFR, as estimated from the creatinine clearance, from a mean of 73 mL/min down to 32 mL/min, after the administration of a nonsteroidal antiinflammatory drug (indomethacin or ibuprofen) to 12 patients with stable hepatic cirrhosis and ascites. Urinary prostaglandin E2 excretion was initially elevated and then fell markedly following therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Zipser, RD, Hoefs JC, Speckhart PF, et al, J Clin Endocrinol Metab 1979; 48:895.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_25_10653=[""].join("\n");
var outline_f10_25_10653=null;
var title_f10_25_10654="Paclitaxel carboplatin ovarian";
var content_f10_25_10654=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F87790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F87790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Weekly paclitaxel with every three week carboplatin chemotherapy for advanced ovarian cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 21 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Carboplatin",
"        </strong>",
"       </td>",
"       <td>",
"        AUC* = 6 mg/mL per min",
"       </td>",
"       <td>",
"        Dilute in 250 mL normal saline (NS) and administer over one hour",
"        <sup>",
"         &Delta;",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Paclitaxel",
"        </strong>",
"       </td>",
"       <td>",
"        80 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL NS and administer over one hour (final concentration range 0.3 to 1.2 mg/mL); special tubing needed",
"        <sup>",
"         &loz;[2]",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        Days 1, 8, and 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        MODERATE on day 1; LOW on days 8 and 15. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Premedicate with dexamethasone plus both an H1 and an H2 receptor antagonist prior to paclitaxel administration. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Carboplatin is an irritant. Paclitaxel can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with G-CSF is not recommended (risk of febrile neutropenia approximately 9 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Each carboplatin dose should be calculated based upon renal function by use of the Calvert formula*. Refer to UpToDate topic on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\". A lower starting dose of paclitaxel may be needed in patients with liver impairment",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential weekly.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Serum electrolytes and liver and renal function prior to each new treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess changes in neurologic function prior to each new treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose modifications for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Initiation of each new treatment cycle should be delayed until the ANC is &gt;1000/cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and/or for a platelet count is &gt;75,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        . The day 8 and 15 doses of paclitaxel should be deleted for an ANC &lt;500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and/or for a platelet count &lt;50,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        . The day 1 carboplatin dose should be decreased to AUC 5 mg/mL per min for febrile neutropenia, ANC &lt;500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        for seven or more days, platelet count less than 10,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        , platelet count between 10,000 and 50,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        with bleeding, or any intracycle hematologic toxicity resulting in a treatment delay for greater than one week. If these hematologic toxicities recur despite carboplatin dose reduction to AUC 5 mg/mL per min, reduce carboplatin dose to AUC 4 mg/mL per min for subsequent cycle. Discontinue treatment for failure to recover adequate blood counts within three weeks.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Renal/hepatic toxicity:",
"        </strong>",
"        Alterations in renal function during therapy may require a recalculation of the carboplatin dose",
"        <sup>",
"         [3]",
"        </sup>",
"        . Paclitaxel dose may need to be adjusted for hepatic impairment on day 1 of each cycle. Refer to UpToDate topics on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurotoxicity:",
"        </strong>",
"        For &ge;grade 2 peripheral neuropathy, reduce paclitaxel dose to 70 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        for all subsequent doses",
"        <sup>",
"         [1]",
"        </sup>",
"        . If neuropathy persists or recurs despite dose reduction, paclitaxel should be further reduced to 60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; G-CSF: granulocyte-colony stimulating factors; CBC: complete blood count; ANC: absolute neutrophil count.",
"     <br/>",
"     * AUC (area under the dose-concentration x time curve) is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula. The Calvert formula is total dose (mg) = (target AUC) x (glomerular filtration rate [GFR] + 25). If using measured serum creatinine, limit the maximal GFR for the calculation to 125 mL/min. Refer to UpToDate topic on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"     <br/>",
"     &Delta; Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Paclitaxel can be administered in NS, 5 percent dextrose in water (D5W) or NS/D5W at varying concentrations between 0.3 to 1.2 mg/mL. Use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through polyethylene-line administration sets with a microporous membrane 0.22 microns or less.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Katsumata N, et al. Lancet 2009; 374:1331.",
"      </li>",
"      <li>",
"       Taxol (paclitaxel) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at file://dailymed.nlm.nih.gov, accessed May 16, 2012).",
"      </li>",
"      <li>",
"       Carboplatin injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at file://dailymed.nlm.nih.gov, accessed May 16, 2012).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_25_10654=[""].join("\n");
var outline_f10_25_10654=null;
var title_f10_25_10655="Gram stain sputum 12E answer";
var content_f10_25_10655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aspergillus fumigatus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 208px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lactophenol-blue wet mount of Aspergillus fumigatus growing on Sabouraud's agar (x400). Note the characteristic \"fruiting bodies\" bearing strands of conidia or spores.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_25_10655=[""].join("\n");
var outline_f10_25_10655=null;
